

CURRICULUM VITAE

PERSONAL DETAILS

NAME: Andrew Lofts Gray
(formerly Andrew Johan Rauch - name changed in 1985)

DATE OF BIRTH: 31 October 1959, Worcester, Western Cape, South Africa

IDENTITY NUMBER: 5910315109087

MARITAL STATUS: Married with 2 children

CONTACT ADDRESSES

Postal	Residential	Business
PO Box 1580 Westville 3630 South Africa	4 Hillside Road Westville 3629 South Africa	Discipline of Pharmaceutical Sciences School of Health Sciences University of KwaZulu-Natal PBag 7 Congella 4013 South Africa

Tel: +27 (0) 31 260 4298 (work)

Fax: +27 (0) 31 260 4338

Cell: +27 (0) 83 459 3422

Email: graya1@ukzn.ac.za
andy@gray.za.net

EDUCATION

SCHOOL : Cape Senior Certificate 1977 ("A" aggregate), Queen's College, Queenstown

UNIVERSITY : BPharm (Rhodes) 1981
MSc(Pharm) (Rhodes) 1984
Thesis title: *Topical immunotherapy for Pseudomonas keratitis: use of antilipopolysaccharide plasma*

CAREER

2002 to date:

Current

Senior lecturer, Division of Pharmacology, Discipline of Pharmaceutical Sciences, School of Health Sciences, Nelson R Mandela College of Health Sciences, University of KwaZulu-Natal (previously the Department of Therapeutics and Medicines Management, Nelson R Mandela School of Medicine, University of KwaZulu-Natal and Department of Experimental and Clinical Pharmacology, School of Medicine, University of Natal).

WHO Collaborating Centre on Pharmaceutical Policy and Evidence Based Practice

Other appointments:

Visiting Fellow, Faculty of Pharmacy, Rhodes University (2014 - date)

Honorary Senior Scientist: Consultant Pharmacist in the Centre for the AIDS Programme of Research in South Africa (CAPRISA)

Chair (2018 - date), **Vice chair** (2015-2017), **Member** (2000-2015) of the Names and Scheduling Advisory Committee of the South African Health Products Regulatory Authority (previously the Medicines Control Council)

Member of the Legal Advisory Committee (2015 - date) of the South African Health Products Regulatory Authority (previously the Medicines Control Council)

Member of the National Essential Medicines List Committee (2013–2016; 2017-2020)

Chair (2018–2021) of the Paediatric Expert Review Committee, National Essential Medicines List Committee (**Co-chair**, 2015-2017)

Member of the WHO Expert Panel on Drug Policies and Management (2007-2011; 2011-2015; 2015-2019; 2019-2023)

Member of the WHO Guideline Steering Group for Family Planning Guidance (2012 - date)

Chair (2012-2020), **Vice-chair** (2010-2011), **Member** (2007-2010) of the Proposal Review Committee of UNITAID (initially of the Interim Expert Advisory Group)

Non-executive Director of JEMBI Health Systems (JEMBI-SAMRC Collaborating Centre in Digital Health Innovation) (2013 to date), **Chairman** (2009-2013)

Chair of the Don McKenzie TB Trust

Chair of the Mike Strong Educational Trust.

Completed

Temporary adviser to the WHO Expert Committee on the Selection and Use of Essential Medicines (2005, 2007)

Chair of the WHO Expert Committee on the Selection and Use of Essential Medicines sub-committee on Medicines for Children (2007, 2008)

Member (at various times co-chair or rapporteur) of the WHO Expert Committee on the Selection and Use of Essential Medicines (2008, 2009, 2010, 2011, 2013)

Member of the WHO Task Force on Hormonal Contraception and HIV (2012)

Member of the Joint United Nations Programme on HIV/AIDS (UNAIDS) Scientific Expert Panel (2013-2016)

Member of the WHO Guidelines Review Committee (2009-2013)

Member of the Medicines Control Council (2015-2018)

Trustee (Director) of LIFELab (East Coast Biotechnology Regional Innovation Centre Trust) (2008-2010)

Member of the Ministerial Task Team on Medical Products (2009)

Member of the Ministerial Task Team on Manufacturing of Active Pharmaceutical Ingredients for Antiretroviral Drugs (2009-2010)

Member of the Ministerial Task Team on the Procurement of HIV test kits (2012)

Member of the Ministerial Task Team on the Procurement of Pharmaceuticals (2012)

Part-time consultant in the Centre for Health Policy, University of the Witwatersrand (2000-2002)

Back-up Pharmacist, ACTG Durban International Clinical Trials Unit (2004-2013)

- 1994-2001: **Lecturer** in the School of Pharmacy and Pharmacology (Division of Pharmacy Practice), University of Durban-Westville.
Other appointments: Guest lecturer, Department of Experimental and Clinical Pharmacology, University of Natal (appointed as Honorary Lecturer, 1998 to 2000); Part-time consultant in the Centre for Health Policy, University of the Witwatersrand (2000-2001); Seconded to the Initiative for Sub-District Support (a project of the Health Systems Trust) as Co-ordinator: Drug Management (1998-2000); Quality Assurance Officer, Biomedical Resource Centre and Product Safety Testing Unit (1994-1998)
- 1993-1994: **Pharmacist** in the Drug Studies Unit, Department of Pharmacology, University of Durban-Westville.
- 1993: Promoted to new position of **Principal Pharmacist (Clinical Services and Staff Training)**, but declined position to take up appointment at the University of Durban-Westville
- 1990-1993: **Senior Pharmacist** (Clinical Services, Staff Training), King Edward VIII Hospital, Durban. **Guest lecturer** for the College of Nursing and the Department of Pharmacology, University of Natal and Department of Pharmacy Practice, Technikon Natal.
- 1988-1990: **Hospital Pharmacist** at King Edward VIII Hospital, Durban. **Guest lecturer** for the College of Nursing.
- 1986-1988: **National Service** in the South African Medical Services (SAMS), finally as Acting Officer Commanding (A/OC) 12 Medical Sub-depot and Staff Officer, Pharmaceuticals (SO3(Pharm)), Natal Medical Command. Rank – Lieutenant.
- 1985-1986: **Hospital Pharmacist** at King Edward VIII Hospital, Durban. **Guest lecturer** for the College of Nursing post- basic courses.
- 1984-1985: Travelled throughout Europe. Worked in London as Caretaker/ Handyman/ Barman
- 1983-1984: **Full-time post-graduate student**, conducted research for Master's degree at University of Natal Medical School under Dr SL Gaffin. After-hours and '**locum-tenens**' work in various retail pharmacies.
- 1982: **Pharmacist intern** at King Edward Pharmacy, Durban (community pharmacy).

AWARDS

- 2020: Honorary Life Membership of the South African Association of Hospital and Institutional Pharmacists
- 2019: Joseph A. Oddis Award for Exceptional Service, International Pharmaceutical Federation
- 2017: Co-author of the Metropolitan Health Award winning best academic presentation at the 31st SAAHIP Conference, Drakensberg
- 2015: Distinguished Old Rhodian Award
- 2014: Donald E. Francke Medal, American Society of Health-system Pharmacists
- 2014: Honorary Member of the Hospital Pharmacy Section, International Pharmaceutical Federation
- 2014: Contributor to the World Health Organization Pocket Book of Hospital Care for Children: Guidelines for the Management of Common Childhood Illnesses 2nd edition, which won the British Medical Association Medical Book of the Year 2014 and also the First Prize in Paediatrics
- 2013: Invited speaker at the Pharmaceutical Society of South Africa Cape Western Province branch Senate Dinner
- 2013: Contributor to the World Health Organization/Health Action International publication "Understanding and responding to pharmaceutical promotion: a practical guide", published in 2010 – the French translation ("Comprendre la promotion pharmaceutique et y répondre. Un manuel pratique") was awarded the Prix Prescrire 2013

- 2013: Fellowship of the International Pharmaceutical Federation
 2013: National Research Foundation (NRF) Sabbatical Grant
 2009: Honorary Life Membership of the Pharmaceutical Society of South Africa
 2000: Co-author of the HHD Award winning podium presentation at the 14th SAAHIP Conference, Hunters Rest
 1999: Fellowship of the Pharmaceutical Society of South Africa
 1996: Pharmacia Upjohn Award for the best publication in the field of Pharmacology by a member of the Academy of Pharmaceutical Sciences in 1995 (with J Botha and R Miller)
 1993: HHD Award, best podium presentation at 7th SAAHIP Conference, Somerset West
 1992: Natal Provincial Administration Merit Award (Class A)
 1990: Natal Provincial Administration Merit Award (Class A)
 1989: Surgeon-General Commendation Certificate
 1988: Officer Commanding Natal Medical Command Commendation Certificate
 1983: Medical Research Council (MRC) Post-Graduate Scholarship (2 years)
 1978: Academic Half-colours, Rhodes University
 1977: Queen's College Trust Scholarship (3 years)
 1977: Cape Provincial Administration Merit Award (3 years)

PUBLICATIONS

Refereed Journals – papers, letters and abstracts

- Schellack N, Coetzee M, Schellack G, Gijzelaar M, Hassim Z, Milne M, Bronkhorst E, Padayachee N, Singh N, Kolman S, **Gray A**. *COVID-19: Guidelines for Pharmacists in South Africa*. Southern African Journal of Infectious Diseases (in press).
- Joosub I, Emará Z, **Gray A**. *Improving policies and practices for the extemporaneous compounding of oral liquid dosage forms in Saudi Arabian hospitals*. European Journal of Hospital Pharmacy (in press; published online 12 August 2019 - doi: 10.1136/ejhpharm-2019-001891).
- Day C, **Gray A**, Ndlovu N, Cois A. *Health and related indicators: interrogating the UHC service coverage index*. In Moeti T, Padarath A (eds). South African Health Review 2019 (pp 215-307). Health Systems Trust, Durban (ISSN 1025-1715; ISBN 978-1-928479-01-7).
- Gray A**, Vawda Y. *Health Legislation and policy*. In Moeti T, Padarath A (eds). South African Health Review 2019 (pp 3-16). Health Systems Trust, Durban (ISSN 1025-1715; ISBN 978-1-928479-01-7).
- Burrone E, Gotham D, **Gray A**, de Joncheere K, Magrini N, Martei YM, Gore C, Kieny M-P. *Patent pooling to increase access to essential medicines*. Bulletin of the World Health Organization 2019; 97(8): 575-577.
- Eccleston C, Fisher E, Cooper TE, Grégoire M-C, Heathcote LC, Krane E, Lord SM, Sethna NF, Anderson A-K, Anderson B, Clinch J, **Gray AL**, Gold JI, Howard RF, Ljungman G, Moore RA, Schechter N, Wiffen PJ, Wilkinson NMR, Williams DG, Wood C, van Tilburg MAL, Zernikow B. *Pharmacological interventions for chronic pain in children: An overview of systematic reviews*. Pain 2019; 160(8): 1698-1707.
- Gray A**, Vawda Y. *Health legislation and policy*. In Rispel LC, Padarath A (eds). South African Health Review 2018 (pp 1-11). Health Systems Trust, Durban (ISSN 1025-1715).
- Day C, **Gray A**, Ndlovu N. *Health and related indicators 2018*. In Rispel LC, Padarath A (eds). South African Health Review 2018 (pp 139-250). Health Systems Trust, Durban (ISSN 1025-1715).
- Simão M, Wirtz VJ, Al-Ansary LA, Hill S, Grove J, **Gray AL**, Nannei C, Hedman L, Das P, Hogerzeil H. *A global accountability mechanism for access to essential medicines*. Lancet 2018; 392(10163): 2418-2420.
- Kredo T, Wiseman R, **Gray A**, Parrish A, Miot J, Cohen K, Jamaloodien K, Blockman M. *How good are our guidelines? Four years of experience with the SAMJ's AGREE II review of submitted clinical practice guidelines*. South African Medical Journal 2018; 108(11): 883-885.
- Vawda YA, **Gray A**. *Transparency in medicines regulatory affairs - reclaiming missed opportunities*. South African Journal of Bioethics and Law 2017; 10(2): 70-74.
- Venter F, Majam M, Jankelowitz L, Adams S, Moorhouse M, Carmona S, Stevens W, Msimanga BR, Allen D, Balani P, Nevhutalu Z, Rhagnath N, Shroufi A, Devillé W, Kazangarare V, van der Wiel R, Templeman H, Puren A, Tucker T, van Cutsem G, Conradie F, Dong K, Chidarikire C, **Gray A**. *South African HIV self-testing policy and guidance considerations*. S Afr J HIV Med. 2017;18(1), a775.

13. **Gray A**, Vawda Y. *Health policy and legislation*. In Padarath A, Barron P (eds). South African Health Review 2017 (pp 13-24). Health Systems Trust, Durban (ISSN 1025-1715).
14. **Gray A**, Suleman F, Pharasi B. *The National Drug Policy – 20 years and still going?* In Padarath A, Barron P (eds). South African Health Review 2017 (pp 49-58). Health Systems Trust, Durban (ISSN 1025-1715).
15. Day C, **Gray A**. *Health and related indicators*. In Padarath A, Barron P (eds). South African Health Review 2017 (pp 217-339). Health Systems Trust, Durban (ISSN 1025-1715).
16. Riley HEM, Steyn PS, Achilles SL, Bass E, **Gray AL**, Polis CB, Kiarie JN. *Hormonal contraceptive methods and HIV: research gaps and programmatic priorities*. Contraception 2017; 96(2): 67-71.
17. Wiffen PJ, Cooper TE, Anderson A-K, **Gray AL**, Grégoire MC, Ljungman G, Zernikow B. *Opioids for cancer-related pain in children and adolescents*. Cochrane Database of Systematic Reviews 2017, Issue 7. Art. No.: CD012564. DOI: 10.1002/14651858.CD012564.pub2.
18. Cooper TE, Fisher E, **Gray AL**, Krane E, Sethna N, van Tilburg MAL, Zernikow B, Wiffen PJ. *Opioids for chronic non-cancer pain in children and adolescents*. Cochrane Database of Systematic Reviews 2017, Issue 7. Art. No.: CD012538. DOI: 10.1002/14651858.CD012538.pub2.
19. Ford N, Vitoria M, Doherty M, **Gray A**. *Candidates for inclusion in a universal antiretroviral regimen: are lamivudine and emtricitabine interchangeable?* Current Opinion in HIV and AIDS 2017; 12(4): 334–338.
20. Wirtz VJ, Hogerzeil HV, **Gray AL**, on behalf of The Lancet Commission on Essential Medicines Policies. *Essential medicines for universal health coverage – Authors' reply (letter)*. Lancet 2017; 389(10082): 1881–1882.
21. Thandar Y, **Gray A**, Botha J, Mosam A. *Topical herbal medicines for atopic eczema: a systematic review of randomized controlled trials*. British Journal of Dermatology 2017; 176(2): 330–343.
22. Nanda K, Stuart GS, Robinson J, **Gray AL**, Tepper NK, Gaffield ME. *Drug interactions between hormonal contraceptives and antiretrovirals: a systematic review*. AIDS 2017; 31(7): 917–952.
23. Wirtz VJ*, Hogerzeil HV*, **Gray AL***, Bigdeli M, de Joncheere CP, Ewen MA, Gyansa-Luttherodt M, Sun J, Luiza VL, Mbindyo RM, Möller H, Moucheraud C, Pécoul B, Rågo L, Rashidian A, Ross-Degnan D, Stephens PN, Teerawattananon Y, 't Hoen EFM, Wagner AK, Yadav P, Reich MR (* co-first authors). *Essential medicines for universal health coverage*. Lancet 2017; 389(10067): 403-476.
24. **Gray AL**, Santa-Ana-Tellez Y, Wirtz VJ. *Impact of the introduction of mandatory generic substitution in South Africa: private sector sales of generic and originator medicines for chronic diseases*. Tropical Medicine and International Health 2016; 21(12): 1504–1512.
25. Gokhul A, Jeena PM, **Gray A**. *Iatrogenic medication errors in a paediatric intensive care unit in Durban, South Africa*. South African Medical Journal 2016; 106(12): 1222-1229.
26. Vermeulen L, Moles R, Collins J, **Gray A**, Sheikh AL, Surugue J, Moss R, Ivey MF, Stevenson J, Takeda Y, Ranjit E, Chaar B, Penn J. *Basel Statements on the Future of Hospital Pharmacy – Revised: From Basel to Bangkok*. American Journal of Health-System Pharmacy 2016; 73(14): 1077-1086.
27. **Gray A**, Vawda Y. *Health policy and legislation*. In Padarath A, King J, Mackie E, Casciola J (eds). South African Health Review 2016 (pp 3-15). Health Systems Trust, Durban (ISSN 1025-1715).
28. Day C, **Gray A**. *Health and related indicators*. In Padarath A, King J, Mackie E, Casciola J (eds). South African Health Review 2016 (pp 243-347). Health Systems Trust, Durban (ISSN 1025-1715).
29. **Gray A**, Riddin J, Jugathpal J. *Health care and pharmacy practice in South Africa*. Canadian Journal of Hospital Pharmacy 2016; 69(1): 36-41.
30. Joosub I, **Gray A**, Cristostomo A, Salam A. *Cost-minimization analysis of imipenem/cilastatin versus meropenem in moderate to severe infections at a tertiary care hospital in Saudi Arabia*. Saudi Pharmaceutical Journal 2015;23(6): 626–634.
31. **Gray AL**, Wirtz VJ, 't Hoen EFM, Reich MR, Hogerzeil HV. *Essential medicines are still essential*. Lancet 2015; 386(10004): 1601-1603.
32. Abdool Karim SS, Abdool Karim Q, Kharsany AB, Baxter C, Grobler AC, Werner L, Kashuba A, Mansoor LE, Samsunder N, Mindel A, Gengiah TN; **CAPRISA 004 Trial Group**. *Tenofovir gel for the prevention of Herpes simplex virus type 2 infection*. New England Journal of Medicine. 2015; 373(6): 530-539.
33. **Gray AL**. *Pharmaceutical pricing and reimbursement policies: perspectives for the future*. Journal of Pharmaceutical Policy and Practice 2015; 8(Suppl 1): K3.
34. **Gray A**, Vawda Y. *Health policy and legislation*. In Padarath A, King J, English R (eds). South African Health Review 2014/2015 (pp3-20). Health Systems Trust, Durban, 2015 (ISSN 1025-1715).
35. Day C, **Gray A**. *Health and related indicators*. In Padarath A, King J, English R (eds). South African Health Review 2014/2015 (pp197-332). Health Systems Trust, Durban, 2015 (ISSN 1025-1715).
36. **Gray AL**, Suleman F. *The relevance of systematic reviews on pharmaceutical policy to low- and middle-income countries*. International Journal of Clinical Pharmacy 2015; 37(5): 717-725.

37. Naidoo K, Grobler AC, Deghaye N, Reddy T, Gengiah S, **Gray A**, Abdool Karim S. *Cost-effectiveness of initiating antiretroviral therapy at different points in TB treatment in HIV-TB co-infected ambulatory patients in South Africa*. Journal of Acquired Immune Deficiency Syndromes 2015; 69(5): 576-584.
38. **Gray A**, Conradie F, Crowley T, Gaede B, Gils T, Shroufi A, Hwang B, Kegakilwe D, Nash J, Pillay P, Stender SC, Venter F, Matthews P. *Improving access to antiretrovirals in rural South Africa – a call to action*. South African Medical Journal 2105; 105(8): 638-640.
39. Massele A, Godman B, Adorka M, Fadare J, **Gray A**, Lubbe M, Ogunleye O, Truter I. *Initiative to progress research on medicine utilisation in Africa – formation of the Medicines Utilization Research in Africa group*. Expert Review of Pharmacoeconomics and Outcomes Research 2015; 15(4): 607-610.
40. **Gray A**. *Starting from the bottom*. American Journal of Health-System Pharmacy 2015; 72(6): 460-465.
41. Jobson R, **Gray A**. *Conflict of interest and regulatory authorities (letter)*. South African Medical Journal 2015; 105(2): 164.
42. Godman B, Malmström RE, Diogene E, **Gray A**, Jayathissa S, Timoney A, Acurcio FA, Alkan A, Brzezinska A, Bucsiacs A, Campbell S, Czczot J, de Bruyn W, Eriksson I, Faridah Aryani MY, Finlayson AE, Fürst J, Garuoliene K, Guerra Júnior AA, Gulbinovič J, Jan S, Joppi R, Kalaba M, Magnusson E, McCullagh L, Miikkulainen K, Ofierska-Sujkowska G, Pedersen H, Selke G, Sermet C, Spillane S, Supian A, Truter I, Vlahovic-Palcevski V, Vien LE, Vural EH, Wale J, Wladysiuk M, Zeng W, Gustafsson LL. *Are new models needed to optimise the utilisation of new medicines to sustain healthcare systems?* Expert Review of Clinical Pharmacology 2015; 8(1): 77-94.
43. **Gray A**, Vawda Y. *Health policy and legislation*. In Padarath A, English R (eds). South African Health Review 2013/2014. Health Systems Trust, Durban, 2014 (ISSN 1025-1715).
44. Day C, **Gray A**. *Health and related indicators*. In Padarath A, English R (eds). South African Health Review 2013/2014. Health Systems Trust, Durban, 2014 (ISSN 1025-1715).
45. Babar Z, **Gray A**, Kiani A, Vogler S, Ballantyne P, Scahill S. *The future of medicines use and access research: using the Journal of Pharmaceutical Policy and Practice as a platform for change?* (editorial) Journal of Pharmaceutical Policy and Practice 2014; 7: 8.
46. **Gray A**. *Medicines shortages – unpicking the evidence from a year in South Africa*. Australasian Medical Journal 2014; 7(5): 208-212.
47. Wiseman R, Cohen K, **Gray A**, Jamaloodien K, Kredo T, Miot J, Parrish A, Taylor B, Blockman M. *AGREE to disagree – critical appraisal and the publication of practice guidelines*. South African Medical Journal 2014; 104(5): 345-346.
48. Naidoo A, Naidoo K, Yende-Zuma N, Gengiah TN, Padayatchi N, **Gray AL**, Bamber S, Nair G, Abdool Karim SS. *Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPIt trial*. Antiviral Therapy 2014; 19(2): 161-169.
49. Ford N, Shubber Z, Hill A, Vitoria M, Doherty M, Mills EJ, **Gray A**. *Comparative efficacy of lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials*. PLoS ONE 2013; 8(11): e79981. doi:10.1371/journal.pone.0079981.
50. **Gray A**, Collins J, Milani B. *Persisting pain in children – ensuring implementation of new guidelines*. European Journal of Hospital Pharmacy – Science and Practice 2013; 20(5): 293–296. DOI:10.1136/ejpharm-2013-000367
51. Lutge EE, **Gray A**, Siegfried N. *The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS*. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD005175. DOI: 10.1002/14651858.CD005175.pub3.
52. Richter M, Venter WDF, **Gray A**. *Enabling HIV self-testing in South Africa*. Southern African Journal of HIV Medicine 2012; 13(4): 186-187.
53. **Gray A**. *Generic policies – a globally-relevant implementation challenge* (editorial). Generics and Biosimilars Initiative (GaBI) Journal 2012; 1(3) DOI: 10.5639/gabij.2012.0103-4.027.
54. Govender D, **Gray A**. *Knowledge of primary school teachers about asthma: a cross-sectional survey in the Umdoni sub-district, KwaZulu-Natal*. South African Family Practice 2012; 54(4): 347-351.
55. **Gray A**, Manasse HR, Jr. *Medicines shortages – a complex global challenge*. Bulletin of the World Health Organization 2012; 90(3): 158-158A. (this was the most down-loaded article in the Bulletin of the WHO in March 2012 – see <http://www.who.int/bulletin/downloads2012/en/index.html>)
56. Gengiah TN, Holford NHG, Botha JH, **Gray AL**, Naidoo K, Abdool Karim SS. *The influence of tuberculosis treatment on efavirenz clearance in HIV-tuberculosis co-infected patients*. European Journal of Clinical Pharmacology 2012; 68(5): 689–695.

57. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, **Gray AL**, Gengiah T, Gengiah S, Naidoo A, Jithoo N, Nair G, El-Sadr WM, Friedland G, Abdool Karim Q. *Integration of antiretroviral therapy with tuberculosis treatment*. New England Journal of Medicine 2011; 365: 1492-1501.
58. **Gray A**. *WHO Essential Medicines List for Children: impact on patient outcomes?* Pediatric Drugs 2011; 13(4): 209-211.
59. Milani B, Magrini N, **Gray A**, Wiffen P, Scholten W. *WHO calls for targeted research on the pharmacological treatment of persisting pain in children with medical illnesses*. Evidence-Based Child Health 2011; 6: 1017–1020.
60. Holloway K, Mathai E, **Gray A**, on behalf of the Community-Based Surveillance of Antimicrobial Use and Resistance in Resource-Constrained Settings Project Group. *Surveillance of antimicrobial resistance in resource-constrained settings - experience from five pilot projects*. Tropical Medicine and International Health 2011; 16(3): 368-374.
61. Holloway K, Mathai E, **Gray A**, on behalf of the Community-Based Surveillance of Antimicrobial Use and Resistance in Resource-Constrained Settings Project Group. *Surveillance of community antimicrobial use in resource-constrained settings - experience from five pilot projects*. Tropical Medicine and International Health 2011; 16(2): 152-161.
62. Gengiah T, **Gray A**, Naidoo K, Abdool Karim Q. *Initiating antiretrovirals during tuberculosis treatment: a drug safety review*. Expert Opinion on Drug Safety 2011; 10(4): 559-574.
63. **Gray A**, Tredree R. *Implementing the Basel Statements on the Future of Hospital Pharmacy – a global challenge*. International Pharmacy Journal 2010; 26(2): 32-34.
64. Abdool Karim Q, Abdool Karim SS, Baxter C, Friedland G, Gengiah T, **Gray A**, Grobler A, Naidoo K, Padayatchi N, El-Sadr W. *The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis*. South African Medical Journal 2010; 100(12): 808-809.
65. Richter M, Venter WDF, **Gray A**. *Home self-testing for HIV: AIDS exceptionalism gone wrong*. South African Medical Journal 2010; 100(1): 636-642.
66. Karim QA, Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; on behalf of the **CAPRISA 004 Trial Group**. *Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women*. Science 2010; 329(5996): 1168-1174.
67. **Gray A**, Holloway K. *Is WHO's Essential Medicines List contributing to rational medicines use in developing countries?* (Abstracts for the 16th World Congress of Basic and Clinical Pharmacology, 17-23 July 2010, Copenhagen, Denmark). Basic & Clinical Pharmacology & Toxicology 2010; 107(Suppl 1): 7-8.
68. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, **Gray A**, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. *Timing of initiation of antiretroviral drugs during tuberculosis therapy*. New England Journal of Medicine 2010; 362: 697-706.
69. **Gray AL**. *Medicine pricing interventions – the South African experience*. Southern Med Review 2009; 2(2): 15-19.
70. **Gray AL**. *Global Conference on the Future of Hospital Pharmacy: Conference welcome*. American Journal of Health-Systems Pharmacy 2009; 66(Suppl 3): S8-S9.
71. **Gray AL**. *Global Conference on the Future of Hospital Pharmacy: Conference conclusions*. American Journal of Health-Systems Pharmacy 2009; 66(Suppl 3): S75-S76.
72. Nicolosi E, **Gray AL**. *Potential costs savings from generic medicines – protecting the Prescribed Minimum Benefits*. South African Family Practice 2009; 51(1): 59-63.
73. Shaw A, **Gray AL**. *Quality of pharmaceutical print advertising in South Africa – assessment of reproductive health advertisements 2001-2005*. South African Family Practice 2009; 51(1): 53-58.
74. **Gray AL**. *Pediatric pharmacotherapy issues in Africa*. Pediatric Drugs 2009; 11(1): 6-8.
75. **Gray A**, Vermeulen L. *The Basel Statements - moving the hospital pharmacy agenda forward*. International Pharmacy Journal 2008; 23(2): 10-13.
76. Podmore SH, Botha JH, **Gray AL**, Esterhuizen T. *Impact of recent evidence on use of hormone therapy in the South African private sector (2001-2005)*. South African Family Practice 2008; 50(6): 42.
77. Podmore SH, Botha JB, **Gray AL**. *Hormone therapy use in the South African public and private sectors 2001-2005 (letter)*. Maturitas 2008; 60: 182-184.
78. Ford N, **Gray A**, Venter WDF. *Tough choices: tenofovir, tenders and treatment*. Southern African Journal of HIV Medicine 2008; 29: 8-10.
79. Hill SR, **Gray A**, Weber M. *Essential medicines for children – setting some standards*. Bulletin of the World Health Organization 2007; 85(9): 650.
80. **Gray A**, Abdool Karim SS. *In reply: Saquinavir and rifampicin for tuberculosis and AIDS: new considerations (letter)*. International Journal of Tuberculosis and Lung Disease 2006 10(11):1302-1303.

81. Singh JA, Abdool Karim SS, Abdool Karim Q, Mlisana K, Williamson C, Gray C, Govender G, **Gray A**. *Enrolling adolescents in research on HIV and other sensitive issues: lessons from South Africa*. PLoS Medicine 2006; 3(7): e180.
82. **Gray A**, Abdool Karim SS, Gengiah TN. *Ritonavir/Saquinavir safety concerns curtail ART options for TB-HIV co-infected patients in resource-constrained settings (letter)*. AIDS 2006; 20(2): 302-303.
83. **Gray A**, Botha J. *Dosing aminoglycosides – from impressions to evidence*. South African Paediatric Review 2005; 2(1): 4-13.
84. **Gray A**. *Insomnia in the elderly – is an evidence-based approach possible?* South African Family Practice 2005; 47(3): 31-36.
85. Chetty R, **Gray AL**. *Inappropriate prescribing in an elderly population: findings from a South African public sector survey*. International Journal of Pharmacy Practice 2004; 12(3): 149-154.
86. **Gray A**, Botha J. *Newer antiepileptic drugs – have recent reviews of the available evidence helped?* South African Paediatric Review 2004; 1(3): 24-33.
87. Botha J, **Gray A**. *Is an evidence-based approach to the selection of antiepileptic drugs possible?* South African Paediatric Review 2004; 1(2): 23-32.
88. **Gray AL**, Matsebula T. *Drug pricing in South Africa – policy and praxis*. Journal of Pharmaceutical Finance, Economics and Policy 2004; 12(2): 95-121. (simultaneously published as a monograph chapter in “International Drug Regulatory Mechanisms” – see below)
89. **Gray A**. *Managing the wheezy infant – what do we “know”?* South African Paediatric Review 2004; 1(1): 19-25.
90. **Gray A**. *Ensuring quality use of medicines – engaging with PBMs and PMBs*. South African Family Practice 2004; 46(1): 43-46.
91. Harries K, **Gray A**. *Quality use of medicines: the young ‘pill’ user with poor cycle control*. South African Family Practice 2003; 45(10): 23-27.
92. **Gray A**. *Quality use of medicines – the child with acute otitis media*. South African Family Practice 2003; 45(9): 42-45.
93. **Gray A**. *Quality use of medicines – the patient with acute cough*. South African Family Practice 2003; 45(8): 22-24.
94. **Gray A**. *Quality use of medicines – the elderly patient with osteoarthritis*. South African Family Practice 2003; 45(7): 54-57.
95. **Gray A**. *Quality use of medicines – weighing SSRIs and TCAs*. South African Family Practice 2003; 45(6): 46-48.
96. **Gray A**, Botha J, Hoffman D. *Quality use of medicines – the postmenopausal woman with osteoporosis*. South African Family Practice 2003; 45(5): 51-53.
97. **Gray A**, Mathibe L. *Quality use of medicines – the vomiting child*. South African Family Practice 2003; 45(4): 20-22.
98. **Gray A**, Harries K. *Quality use of medicines – the teenager with moderate acne*. South African Family Practice 2003; 45(3): 48-50.
99. Laing R, Waning B, **Gray A**, Ford N, ‘t Hoen E. *Twenty Five Years of the WHO Essential Medicines Lists: Progress and Challenges*. Lancet 2003; 361: 1723-1729.
100. **Gray A**. *Quality use of medicines - reconsidering antihypertensive choices*. South African Family Practice 2003; 45(2): 8-10.
101. **Gray A**, Manjra A. *Quality use of medicines – the wheezing infant*. South African Family Practice 2003; 45(1): 66-68.
102. **Gray A**. *Quality use of medicines – the elderly male with acute gout*. South African Family Practice 2003; 26(1): 26-27.
103. **Gray A**. *Quality use of medicines – negotiating asthma guidelines*. South African Family Practice 2002; 25(6): 32-34.
104. **Gray A**. *Quality use of medicines – the febrile child*. South African Family Practice 2002; 25(5): 33-35.
105. **Gray AL**. *Health systems pharmacy in South Africa: opportunities for growth and leadership*. International Pharmacy Journal 2002; 16(1): 13-17.
106. **Gray A**. *Quality use of medicines – type 2 diabetes in the elderly*. South African Family Practice 2002; 25(4): 33-34.
107. **Gray A**. *Quality use of medicines – uncomplicated cystitis*. South African Family Practice 2002; 25(3): 30-32.
108. **Gray A**. *Assuring quality use of medicines*. South African Family Practice 2002; 25(2): 35-36.

109. Smit JA, **Gray AL**, McFadyen ML, Zuma K. *Counting the costs: comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South Africa*. BMC Health Services Research 2001; 1:4.
110. **Gray A**, Smit J. *Improving access to HIV-related drugs in South Africa – a case of colliding interests*. Review of African Political Economy 2000; 27(86): 583-590.
111. McFadyen L, Smit J, **Gray A**, Mestry K. (2000) *Emergency contraception: legal impediments to increased accessibility in South Africa*. Abstracts of the Joint Meeting of the VII World Conference on Clinical Pharmacology and Therapeutics & 4th Congress of the European Association of Clinical Pharmacology and Therapeutics. Velo G, Perucca E (Eds). British Journal of Clinical Pharmacology. Blackwell Science, London.
112. Smit J, McFadyen L, **Gray A**, Zuma K. (2000) *A community-based survey of injectable contraceptive utilization in rural South Africa: patterns of use and experience of side effects*. Abstracts of the Joint Meeting of the VII World Conference on Clinical Pharmacology and Therapeutics & 4th Congress of the European Association of Clinical Pharmacology and Therapeutics. Velo G, Perucca E (Eds). British Journal of Clinical Pharmacology. Blackwell Science, London.
113. Smit J, **Gray A**, McFadyen L. (2000) *Cost implications of injectable contraceptive utilization patterns in South Africa*. Abstracts of the Joint Meeting of the VII World Conference on Clinical Pharmacology and Therapeutics & 4th Congress of the European Association of Clinical Pharmacology and Therapeutics. Velo G, Perucca E (Eds). British Journal of Clinical Pharmacology. Blackwell Science, London.
114. **Gray A**, Seneque M, Smit J. *Reconsidering the need for an epistemology for Pharmacy Practice*. International Journal of Pharmacy Practice 1999; 7(2): 69-70.
115. **Gray AL**, Bodley Smit JA. *Teaching pharmaceutical care principles for PHC*. Medical Teacher 1998; 20(5): 459-462.
116. **Gray AL**, Botha JH, Miller R. *A model for the determination of carbamazepine clearance in children on mono- and polytherapy*. European Journal of Clinical Pharmacology 1998; 54(4): 359-362
117. Naidoo DP, **Gray AL**, Reddy P, Randeree IGH, Naicker IP. *A potential role for a quality assurance approach in the management of hypertension*. South African Medical Journal 1996; 86 (Cardiovascular suppl 5): C262-C264.
118. Botha JH, **Gray AL**, Miller R. *Determination of phenobarbitone clearance values for South African children*. European Journal of Clinical Pharmacology 1995; 48: 381-3.
119. Botha JH, **Gray AL**, Miller R. *A model for estimating individualised valproate clearance values in children*. Journal of Clinical Pharmacology 1995; 35: 1020-4.
120. **Rauch AJ**, Gaffin SL, Welsh NH (1985). *Topical immunotherapy for Pseudomonas keratitis: use of antilipopolysaccharide plasma (abstract)*. Journal of Hospital Infection 1985; 5 (Suppl A): 40.
121. Gaffin SL, Zanotti A, Jordaan JH, Welsh NH, **Rauch A**, Brock-Utne JG, Wells M, Lachman E (1984). *Anti-lipopolysaccharide antibodies successfully treated shock, radiation sickness, surface infections and septic abortions in animals (abstract)*. South African Journal of Science 1984; 80: 130.
122. Welsh NH, **Rauch AJ**, Gaffin SL. *Topical immunotherapy for Pseudomonas keratitis in rabbits: use of antilipopolysaccharide plasma*. British Journal of Ophthalmology 1984, 64: 828-32.

Books/ Book chapters/ Monographs

1. Ndlovu N, Day C, **Gray A**, Cois A. *Universal health coverage index at district level*. In Massyn N, Barron P, Day C, Padarath A (eds). District Health Barometer 2018/2019. Health Systems Trust, Durban, 2020 (pp 239-259 (ISBN: 978-1-928479-04-8).
2. **Gray A**, Osman L, Vawda YA (eds). *Pharmacy Law in South Africa: A Practitioner's Handbook*. LexisNexis South Africa, Durban, 2019 (pp 1-273) (ISBN: 978 0 6390 0525 6 (print); 978 0 6390 0538 6 (e-book)).
3. **Gray A**. *What questions should the national medicines regulatory authority be asking about opioids?* In Waetjen T (ed). Opioids in South Africa: Towards a policy of harm reduction. HSRC Press, Pretoria, 2019 (pp 27-38) (ISBN: 978-0-7969-2575-6).
4. **Gray A**, Jeena P. *Optimal prescribing in the resource-poor setting*. In Barker C, Turner M, Sharland M (eds). Prescribing medicines for children: from drug development to practical administration. Pharmaceutical Press, London, UK, 2019 (pp 265-271) (ISBN 978-0857111357).
5. **Gray A**. *Factors influencing pharmaceutical policy implementation*. In Babar Z (ed). Encyclopedia of Pharmacy Practice and Clinical Pharmacy (1st Edition). Academic Press (Elsevier), Cambridge, USA, 2019 (Vol 2; pp 97-102) (ISBN: 9780128127353).
6. **Gray A**. *Clinical pharmacy professional standards in low- and middle-income countries*. In Babar Z (ed). Encyclopedia of Pharmacy Practice and Clinical Pharmacy (1st Edition). Academic Press (Elsevier), Cambridge, USA, 2019 (Vol 3B; pp 44-47) (ISBN: 9780128127353).

7. Suleman F, **Gray A**. *Pharmaceutical Policies in South Africa*. In Babar Z (ed). *Pharmaceutical Policy in Countries with Developing Healthcare Systems*. Springer International Publishing, Cham, 2017 (pp 285-302) (ISBN 978-3-319-51672-1; DOI 10.1007/978-3-319-51673-8).
8. Padayatchi N, Naidoo K, **Gray A**, Abdool Karim S, Grobler A. *Timing of antiretroviral treatment in HIV-TB co-infected patients: CAPRISA 003 The SAPiT Trial*. In Abdool Karim Q, Abdool Karim SS, Baxter C (eds). *The CAPRISA Clinical Trials: HIV Treatment and Prevention*. Springer International Publishing, Cham, 2017 (pp 107-120) (ISBN 978-3-319-47517-2; DOI 10.1007/978-3-319-47518-9).
9. **Gray A**, Cahn P. *New antiretroviral agents and strategies*. In Abdool Karim SS (ed). *Biomedical AIDS research: recent and upcoming advances*. UNAIDS, Geneva, Switzerland, 2016.
10. **Gray A**, Suleman F, Patel A, Bannenberg W. *South Africa: Implementation of reforms under the National Drug Policy* (WHO/HIS/HGF/CaseStudy/15.9). Health Systems Governance & Financing, World Health Organization, Geneva, 2015. (A case study to accompany Yip W, Hafez R. Improving health system efficiency. Reforms for improving the efficiency of health systems: lessons from 10 country cases WHO/HIS/HGF/SR/15.1). Health Systems Governance & Financing, World Health Organization, Geneva, 2015).
11. **Gray A**, Cahn P. *New antiretroviral agents and strategies*. In Abdool Karim SS (ed). *Biomedical AIDS research: recent and upcoming advances*. UNAIDS, Geneva, Switzerland, 2015 (UNAIDS/JC2723E).
12. **Gray A**, Jeena P, Ojoo A. *Access to medicines – more than just affordability*. In Macleod S, Hill S, Rane A, Koren G (eds). *Optimizing treatment for children in the developing world*. Springer International Publishing, Cham, 2015 (pp 21-32) (ISBN: 978-3-319-15749-8).
13. **Gray A**, Suleman F. *Pharmaceutical pricing in South Africa*. In: Babar Z (ed). *Pharmaceutical Prices in the 21st Century*. Springer International Publishing, Cham, 2015 (pp 251-265) (ISBN 978-3-319-12168-0).
14. **Gray AL**, Vawda YA. *TRIPS, Access to Medicines and Local Production in South Africa*. In Lofgren H, Williams O (eds). *The New Political Economy of Pharmaceuticals. Production, Innovation and TRIPS in the Global South*. Palgrave Macmillan, Basingstoke, 2013 (ISBN: 978-0-230-28463-0, ISBN10: 0-230-28463-9). Available from: <http://www.palgraveconnect.com/pc/doi/10.1057/9781137315854.0015>.
15. Day C, **Gray A**. *Health and related indicators*. In Padarath A, English R (eds). *South African Health Review 2012/2013*. Health Systems Trust, Durban, 2013 (ISBN 978-1-919839-73-8).
16. **Gray A**, Vawda Y, Jack C. *Health policy and legislation*. In Padarath A, English R (eds). *South African Health Review 2012/2013*. Health Systems Trust, Durban, 2013 (ISBN 978-1-919839-73-8).
17. **Gray AL**, Vitoria A (2012). *Technical update on treatment optimization: pharmacological equivalence and clinical interchangeability of lamivudine and emtricitabine: a review of current literature*. World Health Organization, Geneva, 2012 (ISBN 978-924-150381-5).
18. **Gray A**, Vawda Y, Jack C. *Health policy and legislation*. In Padarath A, English R (eds). *South African Health Review 2011*. Health Systems Trust, Durban, 2012 (ISBN: 978-1-919839-71-4).
19. Day C, **Gray A**, Budgell E. *Health and related indicators*. In Padarath A, English R (eds). *South African Health Review 2011*. Health Systems Trust, Durban, 2012 (ISBN: 978-1-919839-71-4).
20. **Gray A**, Suleman F. *Medicines for chronic non-communicable diseases*. In Phaswana-Mafuya N, Tassiopoulos D (eds). *Non-communicable diseases in developing countries*. Nova Science Publishers, Hauppauge NY, 2011 (ISBN: 978-1-61209-996-5).
21. Day C, **Gray A**. *Health and related indicators*. In Fonn S, Padarath A (eds). *South African Health Review 2010*. Health Systems Trust, Durban, 2010 (ISBN: 978-1-919839-69-1).
22. **Gray A**, Hoffman J, Mansfield PR. *Pharmaceutical sales representatives*. In Mintzes B, Mangin D, Hayes L (eds). *Understanding and responding to pharmaceutical promotion: a practical guide*. World Health Organization/Health Action International, Amsterdam, 2010. (also available in French, Spanish and Russian editions)
23. **Gray A**, Goodman B, Terán Puente JM, Mintzes B. *Using unbiased prescribing information*. In Mintzes B, Mangin D, Hayes L (eds). *Understanding and responding to pharmaceutical promotion: a practical guide*. World Health Organization/Health Action International, Amsterdam, 2010. (also available in French, Spanish and Russian editions)
24. **Gray A**. *The challenges of implementing antiretroviral treatment in South Africa*. In Abdool Karim SS and Abdool Karim Q (eds). *HIV/AIDS in South Africa* (2nd edition). Cambridge University Press, Cape Town, 2010 (ISBN: 978-0-521-14793-4).
25. Holloway KA, Mathai E, Sorensen T, **Gray A**. *Community-based surveillance of antimicrobial use and resistance in resource-constrained settings. Report on five pilot projects*. WHO/EMP/MAR/2009.2. World Health Organization, Geneva, 2009.
26. Day C, **Gray A**. *Health and related indicators*. In Barron P, Roma-Reardon J (eds). *South African Health Review 2008*. Health Systems Trust, Durban, 2008 (ISBN: 1-919839-62-3).

27. **Gray A**, Jack C. *Health legislation and policy*. In Barron P, Roma-Reardon J (eds). South African Health Review 2008. Health Systems Trust, Durban, 2008 (ISBN: 1-919839-62-3).
28. Day C, **Gray A**. *Health and related indicators*. In Harrison S, Bhana R, Ntuli A (eds). South African Health Review 2007. Health Systems Trust, Durban, 2007 (ISBN: 1-91839-49-6).
29. **Gray A**. *Developing, registering and using medicines*. In Hassim A, Heywood M and Berger J (eds). Health and Democracy: a Guide to Human Rights, Health Law and Policy in post-apartheid South Africa. Siber Ink, Cape Town, 2007 (ISBN: 978-1-920025-14-4).
30. Day C, **Gray A**. *Health and related indicators*. In Ijumba P, Padarath A (eds). South African Health Review 2006. Health Systems Trust, Durban, 2006 (ISBN: 1-919839-55-0).
31. **Gray A**, Pillay K. *Health legislation and policy*. In Ijumba P, Padarath A (eds). South African Health Review 2006. Health Systems Trust, Durban, 2006 (ISBN: 1-919839-55-0).
32. Day C, **Gray A**. *Health and related indicators*. In Ijumba P, Barron P (eds). South African Health Review 2005. Health Systems Trust, Durban, 2005 (ISBN: 1-91839-49-6).
33. **Gray A**, Govender M, Gengiah T, Singh J. *Health Legislation*. In Ijumba P, Barron P (eds). South African Health Review 2005. Health Systems Trust, Durban, 2005 (ISBN: 1-91839-49-6).
34. **Gray A**, Gengiah T, Naidoo P. *The pharmacist's assistant - a case study of a mid-level worker option*. In Ijumba P, Barron P (eds). South African Health Review 2005. Health Systems Trust, Durban, 2005 (ISBN: 1-91839-49-6).
35. Contributor (with Balasubramaniam K) to: *Medicines*. In Lema C, McCoy D, Morton P, Rowson M, Salvage S, Sexton S (eds). Global Health Watch 2005-2006. Medact, People's Health Movement and the Global Equity Gauge Alliance. Zed Books, London, 2005 (ISBN: 1-84277-568-3).
36. **Gray A**. *The challenges of implementing antiretroviral treatment in South Africa*. In Abdool Karim SS and Abdool Karim Q (eds). HIV/AIDS in South Africa. Cambridge University Press, Cape Town, 2005 (ISBN: 13978-0-521-61629-4)
37. Ijumba P, Poole C, George G, **Gray A**. *Access to antiretroviral therapy*. In Ijumba P, Day C, Ntuli A (eds). South African Health Review 2003/2004. Health Systems Trust, Durban, 2004 (ISBN: 1-919839-35-6).
38. **Gray AL**, Matsebula T. *Drug pricing in South Africa – policy and praxis*. In Wertheimer AI, Smith MC (eds). International Drug Regulatory Mechanisms, Haworth Press, Binghamton, NY, 2004 (ISBN: 0-7890-2548-5).
39. Day C, **Gray A**. *Health and related indicators*. In Ijumba P, Ntuli A, Barron P (eds). South African Health Review 2002. Health Systems Trust, Durban, 2003 (ISBN: 1-919743-74-X).
40. **Gray A**, Matsebula T, Blaauw D, Schneider H, Gilson L. *Policy change in a context of transition: drug policy in South Africa 1989-1999*. Centre for Health Policy, University of the Witwatersrand, 2002.
41. Day C, **Gray A**. *Health and related indicators*. In Ntuli A, Suleman F, Barron P, McCoy D (eds). *South African Health Review 2001*. Health Systems Trust, Durban, 2002 (ISBN: 1-919743-65-0).
42. **Gray A**, Matsebula T. *Drug pricing*. In Crisp N, Ntuli A, Clarke E (eds). South African Health Review 2000. Health Systems Trust, Durban, 2001 (ISBN: 1-919839-16-X).
43. Nadasen S, **Gray A**. *Health legislation*. In Crisp N, Ntuli A, Clarke E (eds). South African Health Review 2000. Health Systems Trust, Durban, 2001 (ISBN: 1-919839-16-X).
44. **Gray A**, Day C. *How should South Africa deal with direct-to-consumer (DTC) advertising in the context of globalisation and the Internet?* HealthLink. Health Systems Trust. May 2000.
45. **Gray A**, Clarke E. *Health and the Mbeki government*. Critical Choices for South African Society April 2000 (No 1). Institute for the Study of Public Policy, University of Cape Town. April 2000.
46. **Gray A**. *Performing an in-depth situation analysis of the drug management system in a health district*. Initiative for Sub-District Support, Health Systems Trust. November 1999.
47. **Gray A**, Suleman F. *Drug policy – from macro development to health district implementation*. In Crisp N, Ntuli A (Eds). South African Health Review 1999. Health Systems Trust, Durban, 1999 (ISBN: 1-919743-53-7).
48. **Gray A**, Strasser S. *ISDS Position Paper: Prescribing and Dispensing by Nurses in District-Level Health Facilities*. Initiative for Sub-District Support, Health Systems Trust. February 1999.
49. **Gray A**. *Equity and the provision of Pharmaceutical Services*. In Ntuli A (Ed). South African Health Review 1998. Health Systems Trust, Durban, 1998 (ISBN: 1-919743-38-3).
50. Suleman F, McCoy D, **Gray A**. *District Drug Management. Lessons learnt from the ISDS experience in the Eastern Cape, KwaZulu-Natal and Northern Cape. Technical Report #9*. Initiative for Sub-District Support, Health Systems Trust. August 1998
51. **Gray A**, Eagles P. *Drug Policy*. In Barron P (Ed). South African Health Review 1997. Health Systems Trust, Durban, 1997 (ISBN: 1-919743-17-0).

Unrefereed Journals

1. Leong TD, Ndlovu T, Jugathpal J, **Gray A**, Mbongo B, Pillay A, Putter S. *Assessing essential medicines in the South African public healthcare sector via section 21*. South African Pharmaceutical Journal 2019; 86(6): 37-40.
2. **Gray A**. *Ethics and professional autonomy*. World Medical Journal 2018; 64(4): 37-39.
3. **Gray A**. *Medicines Control Council – half a century of regulatory progress*. South African Pharmaceutical Journal 2018; 85(1): 87.
4. **Gray A**. *Harm reduction – a neglected policy option in South Africa*. South African Pharmaceutical Journal 2017; 84(2): 51-52.
5. **Gray A**. *Investing in systems in order to advance performance*. South African Pharmaceutical Journal 2016; 83(9): 60-61.
6. **Gray AL**. *HIV self-testing: small steps, more to come*. HIV Nursing Matters 2016; 7(2): 17-19.
7. **Gray A**, van der Merwe L. *Tied up in knots ...or an essential safety net?* South African Pharmaceutical Journal 2016; 83(2): 53-54.
8. **Gray A**, Vermeulen L. *From Basel to Bangkok – the journey continues*. South African Pharmaceutical Journal 2015; 82(10): 35-37.
9. Leong TD, Munsamy J, Reddy M, **Gray A**. *Selection of Essential Medicines in South Africa – a work in progress*. South African Pharmaceutical Journal 2015; 82(3): 39-41.
10. **Gray A**, Pharasi B. *Taking stock – looking back over 20 years in order to look forward*. South African Pharmaceutical Journal 2014; 81(5): 37-39.
11. **Gray A**. *Biosimilars in rheumatology – has South Africa “jumped the gun”?* South African Rheumatology Journal 2013; 5(2): 12-15.
12. **Gray AL**. *Lessons from the FIP Centennial Congress and the Ministers’ Summit*. South African Pharmaceutical Journal 2013; 80(3): 34-36.
13. **Gray A**, Suleman F. *Training for clinical pharmacists – plat du jour or smörgåsbord?* South African Pharmaceutical Journal 2012; 79(2): 38-40.
14. **Gray A**. *Prescribing and dispensing by nurses – neglected steps in the legislative process*. HIV Nursing 2010; 1(2): 28-31.
15. **Gray A**. *Global standards, South African practice – report of a workshop*. South African Pharmaceutical Journal 2010; 77(5): 45-48.
16. **Gray A**. *Looking through the mirror ... seeing the envisioned future?* South African Pharmaceutical Journal 2010; 77(3): 50-51.
17. **Gray A**. *Collaborative practice – more than just task shifting*. South African Pharmaceutical Journal 2010; 77(1): 44-47.
18. **Gray A**. *Occupation-specific dispensation – an exercise in bad faith negotiations or promise for the future?* South African Pharmaceutical Journal 2009; 76(10): 52-56.
19. **Gray A**. *The Global Conference on the Future of Hospital Pharmacy – from evidence to consensus and action*. South African Pharmaceutical Journal 2009; 76(1): 42-44.
20. **Gray A**. *Good Pharmacy Practice and Safety – missing pieces of the jigsaw?* South African Pharmaceutical Journal 2008; 75(5): 34-36.
21. **Gray A**. *Medication safety and medication errors - where are we?* South African Pharmaceutical Journal 2008; 75(4): 24-26.
22. **Gray A**. *The public sector strike – confronting reality*. South African Pharmaceutical Journal 2007; 74(7): 18-20.
23. **Gray A**. *Using the Good Pharmacy Practice Guidelines to advance patient safety*. South African Pharmaceutical Journal 2007; 74(5): 26-28.
24. **Gray A**. *SAAHIP – the historic 50th Annual General Meeting and 21st Conference*. South African Pharmaceutical Journal 2007; 74(4): 50-51.
25. Mathibe LJ, **Gray A**. *Health-related quality of life of breast cancer patients; before, during and after chemotherapy*. Patient Reported Outcomes Newsletter 2006; 37 (Fall): 32-33.
26. **Gray A**, Essack S. *Monitoring antibiotic use and resistance – a pilot project in South Africa*. Essential Drugs Monitor 2005; 34: 20.
27. **Gray AL**. *New Medicines Act and Regulations – opportunities for professional practice*. Journal of Modern Pharmacy 2003; 10(6): 4-6.
28. **Gray A**. *Quality and safety of pharmacy care – a way forward*. Specialist Forum 2003; 3(2): 35-45.
29. **Gray AL**. *Health systems pharmacy in South Africa: equity bound?* Specialist Forum 2002; 2(2): 44-48.
30. **Gray A**, Day C. *Regulating direct-to-consumer (DTC) advertising in a globalised and connected world*. South African Pharmaceutical Journal 2000; 67(7): 12-14.

31. **Gray A**, Day C, Rochat C. *E-pharmacy – from bricks to clicks OR should Luddites learn to click?* South African Pharmaceutical Journal 2000; 67(7): 39.
32. **Gray A**. *An “essential” response to the issue of access to drugs?* AIDS Bulletin 2000; 9(1): 4-6.
33. **Gray A**. *Public-private partnerships in Pharmacy*. South African Pharmaceutical Journal 2000; 67(3): 6.
34. **Gray A**. *Pharmacy staffing: problems and pitfalls*. South African Pharmaceutical Journal 2000; 67(2): 4.
35. McFadyen ML, Smit JA, **Gray AL**. *Emergency contraception: legal and ethical dilemmas facing the pharmacist*. South African Pharmaceutical Journal 1999; 66(2): 41-42.
36. **Gray A**, Mielke B and White M. *Pharmacy and the academic health service complex – bright vistas, storm clouds or just more drizzle?* South African Pharmaceutical Journal 1999; 66(1): 11-12.
37. **Gray AL**, Smit JA. *Changing to district-based pharmaceutical services: mountain or molehill?* South African Pharmaceutical Journal. 1997; 64(11/12): 376-7.
38. **Gray AL**, Smit JA. *Personnel appraisal in the Public Service: a social validity analysis*. South African Pharmaceutical Journal 1997; 64(7); 209-11.
39. **Gray AL**, Smit JA. *Scenario planning for pharmacy: the place of the profession in the District Health System*. South African Pharmaceutical Journal 1996; 63(11): 458-9.
40. **Gray AL**. *The application of Pharmaceutical Care principles in the South African hospital and institutional sector*. South African Pharmaceutical Journal 1995; 62(9): 318-9.
41. **Rauch AJ**, Welsh NH, Gaffin SL. *Topical immunotherapy with Anti-LPS plasma: use in a guinea-pig model of Pseudomonas keratitis*. Ark 1984, 6: 4-6.

Other publications

1. Fischer J, **Gray A**, Dabade G. *The global situation of (lack of) access to medicines*. MEZIS Nachrichten 2/16, August 2016 (<https://www.mezis.de/wp-content/uploads/2016/09/N162e-online.pdf>).
2. **Gray A**. *Our medicines regulatory authority – plans for reform in South Africa*. NSP Review 2012; issue 3 (<http://www.nspreview.org/2012/10/03/our-medicines-regulatory-authority-plans-for-reform-in-south-africa/>)
3. **Gray A**. *Increasing use of generic antiretrovirals by PEPFAR programs*. Reviewed for Journal WATCH AIDS Clinical Care 2010; 22(10): 82-89.
4. **Gray AL**. *Opposition to generic substitution*. Modern Generics, August 2007. Issued as a supplement to Modern Pharmacy and Modern Medicine.
5. **Gray A**. *Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception: RHL commentary*. The WHO Reproductive Health Library. World Health Organization, Geneva. 15 December 2006.
6. **Gray AL**. *AIDS und Ernährung in Südafrika - Konfusion in der Politik*. Pharma-Brief Issue 2, March/April 2003.
7. **Gray A**. *Nurses and the quest for rational drug use*. HST Update Issue 46, September 1999.
8. **Gray A**. *Collecting and using Drug Use Indicators in Districts*. Kwik Skwiz #19. Initiative for Sub-District Support, Health Systems Trust. June 1999.
9. Smit J, **Gray A**. *Legal constraints to the provision of emergency contraception pills*. Emergency Contraception Research Group, Africa Centre for Population Studies and Reproductive Health, and Pharmaceutical Policy Practice Group (UDW). June 1999.
10. Clark E, **Gray A**. *Health and the Law – what's new since 1994?* HST Update Issue 39, January 1999
11. **Gray A**. *Computers and district-level pharmaceutical services*. HealthLink News Issue 10, December 1998.
12. **Gray A**. *The registration of traditional medicines – a new Medicines Bill*. HST Update Issue 37, October 1998.
13. **Gray A**. *Using stock cards to improve drug management*. KwikSkwiz #13. Initiative for Sub-District Support, Health Systems Trust. August 1998.

Editorials

A series in the South African Pharmaceutical Journal, entitled “*Shades of Gray*”: South African Pharmaceutical Journal 1998-2000, volumes 65(4) to 67(3).

RESEARCH AND CONSULTANCY REPORTS

1. **Gray A** (2019). *Review of WHO safety and vigilance activities*. Prepared for the Department of Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland.

2. **Gray A** (2018). *Report on updating the World Health Organization publication “Drug and Therapeutics Committees: A Practical Guide” to incorporate antimicrobial stewardship*. Prepared for the Department of Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland.
3. **Gray A**, Pharasi B (chair), Quinot G, Suleman F, Dubula V (2013). *Report of the Ministerial Task Team on procurement: ensuring medicines availability at facilities through innovative procurement and distribution models*. Prepared for the National Department of Health.
4. **Gray A** (2013). *Strategic Report on Development and Cooperation in the Pharmaceutical Sectors in the BRICS Countries: Medicines for HIV/AIDS, Tuberculosis, Malaria and Priority Medicines for Non-communicable Diseases*. Prepared for UNAIDS, Department of Public Health, Innovation and Intellectual Property and Department of Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland.
5. **Gray A** (2012). *Priority medicines for mothers and children 2011: technical paper*. Prepared for the Department of Essential Medicines and Pharmaceutical Policy, World Health Organization, Geneva, Switzerland.
6. **Gray A** (2012). *Comparative efficacy and safety of lamivudine and emtricitabine: a systematic review*. Prepared for the Department of HIV/AIDS, World Health Organization, Geneva, Switzerland.
7. **Gray A** (2012). *The potential pharmacological equivalence and clinical interchangeability of lamivudine and emtricitabine*. Prepared for the Department of HIV/AIDS, World Health Organization, Geneva, Switzerland.
8. Technical chair of the Guideline Development Group for the WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses (2012)
(http://apps.who.int/iris/bitstream/10665/44540/1/9789241548120_Guidelines.pdf; ISBN 978 92 4 154812 0)
9. **Gray A**, Smit J, Adler A (2010). *Evaluation of the Continuous Identification of Research Evidence (CIRE) system & guideline development process of the Promoting Family Planning Unit, Department of Reproductive Health and Research, World Health Organization*. Prepared for the Promoting Family Planning Unit (PFP), Department of Reproductive Health and Research (RHR), World Health Organization, Geneva, Switzerland.
10. **Gray AL**, Suleman F (2010). *Overview of systematic reviews on pharmaceutical policy, and their relevance to low- and middle-income countries*. Prepared for the Alliance for Health Policy and System Research, World Health Organization, Geneva, Switzerland.
11. **Gray AL** (2008). *Review of essential medicine priorities in ear, nose and throat conditions in children*. Prepared for the Department of Policy, Access and Rational Use (PAR)/Medicines Policy and Standards (PSM), World Health Organization, Geneva, Switzerland.
12. **Gray AL**, Suleman F (2007). *Assessment of implementation, impact and process of the WHO Medicines Strategy 2004-2007*. Prepared for the Department of Technical Cooperation on Essential Drugs and Traditional Medicine (TCM), World Health Organization, Geneva, Switzerland.
13. **Gray AL**, Smit J, Manzini N, Beksinska M (2006). *Systematic review of contraceptive medicines: “Does choice make a difference?”* Prepared for the Department of Reproductive Health and Research (RHR) and the Department of Policy, Access and Rational Use (PAR)/Medicines Policy and Standards (PSM), World Health Organization, Geneva, Switzerland.
14. HealthNet South Africa (2006). HealthNet South Africa Pilot Project. A Potential Niche for HealthNet in South Africa. Prepared for the Overbrook Foundation and SatelLife, Boston, USA.
15. **Gray A** (2006). *Systematic review of the safety of buprenorphine, methadone and naltrexone*. Prepared for Management of Substance Abuse (MSB), Department of Mental Health and Substance Abuse (MSD), World Health Organization, Geneva, Switzerland.
16. **Gray A** (2004). *Access to Medicines and Drug Regulation in Developing Countries: a Resource Guide for DFID*. Prepared for the United Kingdom Department for International Development Health Systems Resource Centre. (http://www.dfidhealthrc.org/shared/publications/Issues_papers/ATM/Gray.pdf)
17. Health Research for Action (2002/3). *Lesotho pharmaceutical sector review*. Prepared for the Ministry of Health and Welfare, Government of the Kingdom of Lesotho.
18. Trouiller P, Salmen R, Myhr K, Folb P, Weerasuriya K, **Gray A** (2002). *The globalization of regulatory requirements, and the development and availability of medicinal products in developing countries: quality, efficacy and safety issues*. Prepared for the MSF/DND/Working Group: The Crisis of Neglected Diseases, Developing Treatments and Ensuring Access Conference, New York.
19. Bellis K, Asia I, **Gray A** (2000). *Analysis of progress with the DFID-funded South African Drug Action Programme*. Prepared for the Department for International Development (UK).

20. **Gray AL** (2000). *Penetrating the local government market: examining options in the Cape Town Metropolitan area*. Prepared for Vuna Healthcare Logistics.
21. Trap B, **Gray A**, Khomo NE, Bellis K (1998). *Joint Mid-term Review of the South African Drug Action Programme*. Prepared for the World Health Organisation, Department for International Development (UK) and National Department of Health (SA).
22. Conry I, Fitzpatrick RK, **Gray A**, Hattingh HL, Putter SJ, Summers RS (1998). *Staffing Norms for Pharmaceutical Services in the Public Sector*. Prepared for the South African Pharmacy Council.
23. **Gray AL** (1998). *Staffing Norms Research Project – Pilot Study Report*. Prepared for the Interim Pharmacy Council of South Africa.
24. **Gray A**, Smit J (1997). *Paths to the establishment of a District Health System in the Outer West: an exploration of alternative routes*. Prepared for The Valley Trust.
25. Bhagwanjee AM, **Gray AL**, Smit JA, Haffajee MR, Parekh A, Moonilal R (1996). *Research capacity development: situational analysis and strategic plan*. Interdisciplinary Health Group Research Series 3(1). University of Durban-Westville.
26. Smit JA, **Gray AL**, Bhagwanjee AM (1995). *Capacity assessment of the Faculty of Health Sciences: implications for regional resource rationalisation*. Technical Report 7: Research and Policy Studies Final Technical and Financial Report, Vol 2: pp39-51. Interdisciplinary Health Group, University of Durban-Westville.
27. Bhagwanjee AM, Smit JA, **Gray AL** (1995). *An evaluation of the research capacity of the Faculty of Health Sciences: towards Essential National Health Research (ENHR)*. Technical Report 8: Research and Policy Studies Final Technical and Financial Report, Vol 2: pp52-60. Interdisciplinary Health Group, University of Durban-Westville.
28. Bhagwanjee A, Smit J, **Gray A**, Moodley V, Haffajee R (1995). *Meeting South African health and education imperatives: a model for institutional reconstruction and development*. Technical Report 12: Research and Policy Studies Final Technical and Financial Report, Vol 3: pp1-45. Interdisciplinary Health Group, University of Durban-Westville.
29. Miller R, Partab P, **Gray A**, Chetty M (1993). *Comparative bioavailability of two gemfibrozil products*. Drug Studies Unit, University of Durban-Westville. Prepared for Warner-Lambert SA (Pty) Ltd.
30. Miller R, Partab P, **Gray A**, Chetty M (1993). *Comparative bioavailability of two phenytoin products*. Drug Studies Unit, University of Durban-Westville. Prepared for Warner-Lambert SA (Pty) Ltd.

CONFERENCE, KEYNOTE and INVITED PRESENTATIONS

Presenting authors are indicated in bold type (venue in South Africa unless stated otherwise).

1. **Gray A** (2020). *National Health Insurance Bill – issues of content and process*. Presented at the 34th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Centurion.
2. **Gray A** (2019). *National Health Insurance Bill – issues of content and process*. Presented at the Health Systems Trust, Durban.
3. **Gray A** (2019). *Pharmacotherapy of dementia – dealing with the ‘unknown unknowns’*. Presented at the Pharmaceutical Society of South Africa/South African Association of Hospital and Institutional Pharmacists KwaZulu-Natal Inland branch, Pietermaritzburg.
4. **Gray A** (2019). *Pharmacy – where we are*. Presented at the PSSA Pharmacy Symposium, Gallagher Estate.
5. **Gray A** (2019). *Medicinal cannabis – trying to keep up with shifting legal provisions*. Presented at the 3rd National Pharmacy Conference, Sun City.
6. **Gray A** (2019). *Entrenching leadership skills in the pharmacy workforce; challenges and opportunities*. Presented at the 3rd National Pharmacy Conference, Sun City.
7. **Gray A** (2019). *The soul of Pharmacy*. Presented at the 3rd National Pharmacy Conference, Sun City.
8. **Gray A**, Day C (2019). *Indicators of policy implementation - a palliative care example*. Presented at the Department of Public Health Medicine Journal Club, University of KwaZulu-Natal.
9. **Gray A**, Day C (2019). *Use of utilisation data to track implementation of a policy: the challenges of palliative care and the proposed morphine monitoring system*. Presented at the 5th Medicines Utilisation Research in Africa (MURIA) symposium, North West University, Potchefstroom.
10. **Gray A** (2019). *Medicinal cannabis – what are the implications for Pharmacy?* Presented at the Pharmaceutical Society of South Africa, Cape Western Province branch, Cape Town.
11. **Gray A** (2019). *Medicinal cannabis: keeping up with the changes*. Presented at the South African Association of Pharmacists in Industry Conference, Pretoria.

12. **Gray A** (2018). *Trends in the treatment of hypertension*. Presented at the Pharmaceutical Society of South Africa/South African Association of Hospital and Institutional Pharmacists KwaZulu-Natal Inland branch Annual General Meeting, Pietermaritzburg.
13. **Gray A** (2018). *Medicinal cannabis – shifting sands*. Presented at the 26th Lebanese Order of Pharmacists Conference, Beirut, Lebanon.
14. **Gray A** (2018). *Global perspectives on viral hepatitis infections*. Presented at the American College of Clinical Pharmacy Global Conference, Seattle, USA.
15. **Gray A** (2018). *Innovative methods of using evidence-based medicine in patient-centred care*. Presented at the South African Medical Association Conference, Sun City.
16. **Gray A, Day C** (2018). *Access to appropriate pain relief in palliative care – developing a suitable indicator*. Presented at the Pharmaceutical Society of South Africa Conference, Boksburg.
17. **Gray A, Day C**, on behalf of the Drug Availability Task Team, Steering Committee on Palliative Care, South Africa (2018). *Enabling and measuring access to palliative care medicines*. Presented at the 3rd International Children’s Palliative Care Network Conference, Durban.
18. **Gray A** (2018). *Regulating pharmaceuticals: all about change in 2018*. Presented at the Forum for Professional Nurse Leaders Conference, Sandton.
19. **Gray A** (2018). *Ethics and professional autonomy*. Presented at the 5th World Health Professions Regulation Conference, Geneva, Switzerland.
20. **Gray A** (2018). *What are the opportunities for the review of new medicines in South Africa with the establishment of the South African Health Products Regulatory Authority (SAHPRA)?* Presented at the Centre for Innovation in Regulatory Science Workshop on Practical Implementation of Reliance Models, Sandton.
21. **Gray A** (2017). *Value-based price efficiency modelling for South Africa, outcomes-based price and access models based on international principles/successes*. Presented at the ISPOR South Africa Chapter Annual Congress 2017, Sandton.
22. **Gray A** (2017). *Opportunities for nurturing the soul of pharmacy: What can be done today to nurture our profession?* Presented at the 77th Congress of the International Pharmaceutical Federation (World Congress of Pharmacy and Pharmaceutical Sciences 2017), Seoul, South Korea.
23. **Gray A** (2017). *Medicinal cannabis – navigating a complex pathway*. Presented at the Aromatherapy Association of South Africa Conference, Salt Rock.
24. **Gray A** (2017). *Current drugs policy perspectives and pharmacological dilemmas for South Africa: what questions should the national medicines regulatory authority be asking?* Presented at the Johannesburg Institute of Advanced Study workshop “Opioids and Harm Reduction in South Africa: Opening a Multidisciplinary Conversation”, Johannesburg.
25. **Gray A** (2017). *Transparency in SAHPRA – what should industry’s position be?* Presented at the Southern African Pharmaceutical Regulatory Affairs Association, Midrand.
26. **Gray A** (2017). *Advertising and the Schedule 1/ Schedule 2 split – logical, necessary?* Presented at the Southern African Pharmaceutical Regulatory Affairs Association, Midrand.
27. **Gray A** (2017). *The NHI policy process – where are we now?* Presented at the Pharmaceutical Society of South Africa Conference, Fourways.
28. Nanda K, Stuart GS, Robinson J, **Gray A**, Gaffield ME (2017). *Drug interactions between hormonal contraceptives and antiretrovirals: a systematic review*. Presented at the 31st Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Drakensberg (won the Metropolitan Health award for the best academic presentation).
29. **Gray A, Day C** (2017). *Joining the dots – making sense of medicines utilisation data*. Presented at the 31st Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Drakensberg.
30. Nanda K, Stuart GS, Robinson J, **Gray A**, Tepper NK, Gaffield ME (2017). *Interactions between hormonal contraceptive methods and antiretroviral therapy*. Presented at the Royal College of Obstetricians and Gynaecologists World Congress 2017, Cape Town.
31. **Cooper TE**, Wiffen PE, Anderson AK, Gray A, Gregoire MC, Ljungman G, Zernikow B, Eccleston CE (2016). *Opioids for cancer pain in children and adolescents: Part 1 of a Cochrane Suite of Paediatric Reviews* (Poster PW0110). Presented at the 16th World Congress on Pain, Yokohama, Japan.
32. **Gray AL**. *Policy-making process at the World Health Organization (WHO)* (2016). Presented at the 76th Congress of the International Pharmaceutical Federation (World Congress of Pharmacy and Pharmaceutical Sciences 2016), Buenos Aires, Argentina.

33. Nanda K, Stuart GS, Robinson J, **Gray A**, Tepper NK, Gaffield ME (2016). *Interactions between HC methods and ART – updated systematic review*. Presented at the 21st International AIDS Conference, Durban.
34. **Gray AL** (2016). *Clinical issues and debates in contraception for women and adolescents living with HIV*. Presented at the 21st International AIDS Conference, Durban.
35. **Gray AL** (2016). *What's the problem with TB medicines and what needs to happen so that new medicines become available?* Presented at the Interfaith Preconference to AIDS 2016, Durban.
36. **Gray AL** (2016). *The missing link for CAMS: various Acts and regulations*. Presented at the SMASA/HPA complementary and alternative medicine industry workshop, Midrand.
37. **Gray AL** (2016). *Legal limitations for nurse prescribers: a focus on dispensing*. Presented at the Forum for Professional Nurse Leaders Conference, Sandton.
38. **Gray AL** (2016). *Medicine policies - antiretrovirals in resource-constrained settings*. Presented at the Kheth'Impilo Pharmacy Symposium, Durbanville.
39. **Gray AL** (2016). *North South East West- harmonization of guidelines*. Presented at the South African Association of Pharmacists in Industry (SAAPI) Conference, Pretoria.
40. Gray AL, **Santa-Ana-Tellez Y**, Wirtz VJ (2016). *Effect of mandatory substitution on generic medicines consumption in South Africa*. Presented at the WHO Collaborating Centre for Pharmaceutical Policy and Regulation Winter Meeting January 2016, Utrecht, The Netherlands.
41. **Gray AL** (2015). *Pharmaceutical pricing and reimbursement policies: perspectives for the future*. Keynote address presented at the 3rd International PPRI Conference 2015, Vienna, Austria.
42. **Gray A** (2015). *Sustainable remuneration: Translating these findings into strategy and policies: a panel discussion*. Presented at the 75th Congress of the International Pharmaceutical Federation (World Congress of Pharmacy and Pharmaceutical Sciences 2015), Düsseldorf, Germany.
43. **Gray A** (2015). *Expanding the range of authorised prescribers – a very slow tango*. Presented at the Academy of Pharmaceutical Sciences/South African Association of Pharmacists in Industry Conference, Sandton.
44. **Gray AL**, Santa-Ana-Tellez Y, Wirtz VJ (2015). *Did the introduction of mandatory offer of generic substitution have a quantifiable effect in South Africa?* Presented at the 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, USA.
45. **Gray A** (2015). *Antiretrovirals in resource-constrained settings – role of responsible medicines use*. Kheth'Impilo Pharmacy Symposium, Salt Rock.
46. **Gray A** (2015). *Medical device regulation – in flux*. Presented at the Expanding Dual Protection Options for Women in South Africa: the SILCS Diaphragm satellite session, 7th South African AIDS Conference, Durban.
47. **Gray A** (2015). *Applying the latest HIV guidelines – challenges and opportunities*. Presented at the 5th Pharmaceutical Care Conference, Muscat, Sultanate of Oman.
48. **Gray A** (2015). *The global challenge of new and expensive medicines*. Presented at the 5th Pharmaceutical Care Conference, Muscat, Sultanate of Oman.
49. **Gray A** (2014). *Prescribing in South Africa: what's next?* Presented at the 2nd Southern African HIV Clinicians Society Conference, Cape Town.
50. **Gray A** (2014). *Self-testing without counselling*. Presented at the 2nd Southern African HIV Clinicians Society Conference, Cape Town.
51. **Gray A** (2014). *Risks of HIV/AIDS treatment interruptions*. Presented at the 74th Congress of the International Pharmaceutical Federation (World Congress of Pharmacy and Pharmaceutical Sciences 2014), Bangkok, Thailand.
52. **Gray A** (2014). *Selecting medicines for off-label indications - a global perspective*. Presented at the 17th World Conference of Basic and Clinical Pharmacology, Cape Town.
53. **Gray A** (2014). *Risk management in South Africa - are we missing something?* Presented at the South African Association of Pharmacists in Industry Conference, Sandton.
54. **Gray A** (2014). *Generics, clones, biosimilars and substitution - overlaps and differences*. Presented at Netcare Umghlanga Hospital.
55. **Gray A** (2014). *Empowering pharmacy practice - potential gains*. Keynote address presented at the 4th Pharmaceutical Care Conference, Muscat, Sultanate of Oman.
56. **Gray A** (2013). *Ethical responsibility vs funding control*. Presented at the Joint Conference of the Independent Community Pharmacies Association, Academy of Pharmaceutical Sciences and South African Society of Basic and Clinical Pharmacology, Cape Town.
57. **Gray A** (2013). *Five hundred billion reasons to do better – the FIP Centennial promise*. Gauteng Annual Pharmaceutical Services Conference, St George's Hotel, Irene.

58. **Gray A** (2013). *Hospital Pharmacy in South Africa – some reflections on where we are now*. Life Healthcare Conference, Rosebank.
59. **Gray A** (2013). *How have the Basel Statements helped pharmacists in Africa manage complex patients? - A case study*. Presented at the 73rd Congress of the International Pharmaceutical Federation (World Congress of Pharmacy and Pharmaceutical Sciences 2013), Dublin, Ireland.
60. **Gray A** (2013). *Responsible use of medicines: saving lives, saving money*. Presented at the 2013 Conference of the Pharmaceutical Society of Ghana, Kumasi, Ghana.
61. **Gray A** (2013). *The Role of academia in responsible use of medicines*. Presented at the 2013 Conference of the Pharmaceutical Society of Ghana, Kumasi, Ghana.
62. **Gray A, Besançon L** (2013). *Causes and contributing factors of the medicines shortage*. Presented at the joint International Pharmaceutical Federation/Canadian Pharmacists Association International Summit on Medicine Shortages, Toronto, Canada
63. **Gray A** (2013). *Five hundred billions reasons to do better – the Centennial promise*. Presented at the 27th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Drakensberg.
64. **Gray A** (2013). *Scheduling and naming of medicines in South Africa – an update*. South African Association of Pharmacists in Industry conference, Pretoria.
65. **Gray A** (2012). *Ensuring patient safety – a hospital pharmacy imperative*. Presented at the 20th Annual Congress of the Ordre des Pharmaciens du Liban, Beirut, Lebanon.
66. **Gray A** (2012). *What the clinical pharmacist should know about drug transporters*. Presented at the 72nd Congress of the International Pharmaceutical Federation (World Congress of Pharmacy and Pharmaceutical Sciences 2012), Amsterdam, The Netherlands.
67. **Gray A** (2012). *Paediatric dosing*. Presented at the SAAHIP KwaZulu-Natal Coastal branch, Durban.
68. **Gray A** (2012). *National Drug Policy – what needs to be covered for the NHI?* Presented as a Continuing Professional Development lecture, Durban.
69. **Gray A** (2012). *Rational use of medicines – emerging challenges in Africa*. Presented at the 5th All Africa Congress on Basic and Clinical Pharmacology, Accra, Ghana.
70. **Gray A** (2012). *Tuberculosis in South Africa today – an overview*. Presented at the 3rd People’s Health Assembly, Cape Town.
71. **Gray A** (2012) *Management of cough in children*. Presented at the Pharmaceutical Society of South Africa Conference, Johannesburg.
72. **Gray A, Suleman F** (2011). *Overview of systematic reviews on pharmaceutical policy and their relevance to low- and middle-income countries*. Presented at the 3rd International Conference on Improving Use of Medicines, Antalya, Turkey.
73. **Holloway KA, Mathai E, Gray A** (2011). *Surveillance of antimicrobial use in resource-constrained community settings*. Presented at the 3rd International Conference on Improving Use of Medicines, Antalya, Turkey.
74. **Holloway KA, Mathai E, Gray A** (2011). *Surveillance of antimicrobial resistance in resource-constrained community settings*. Presented at the 3rd International Conference on Improving Use of Medicines, Antalya, Turkey.
75. **Abegunde DO, Holloway K, Mathai E, Gray A, Ondari C, Chandry S** (2011). *Behavioural model for community-based antimicrobial resistance, Vellore, India*. Presented at the 3rd International Conference on Improving Use of Medicines, Antalya, Turkey.
76. **Gray AL** (2011). *Essential Medicines List for Children – the necessity and the challenges*. Presented at the 6th International Conference on Pharmaceutical and Pharmacological Sciences, Durban.
77. **Gray AL** (2011). *What is advanced practice and who is doing it?* Presented at the 71st Congress of the International Pharmaceutical Federation (World Congress of Pharmacy and Pharmaceutical Sciences 2011), Hyderabad, India.
78. **Gray AL** (2011). *Developing and implementing the WHO Essential Medicines List for Children*. Presented at the 71st Congress of the International Pharmaceutical Federation (World Congress of Pharmacy and Pharmaceutical Sciences 2011), Hyderabad, India.
79. **Richter M, WDF Venter, Gray A** (2011). *The time for home self-testing for HIV is now*. Presented at the 5th South African AIDS Conference, Durban.
80. **Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, Gengiah T, Gengiah S, Naidoo A, Jithoo N, Nair G, El-Sadr WM, Friedland G, Abdool Karim Q** (2011). *Optimal timing of antiretroviral therapy during tuberculosis treatment: The SAPiT trial*. Presented at the 18th Conference on Retroviruses and Opportunistic Infections, Boston, USA.

81. **Gray AL** (2010). *Seamless care – from hospital to open care*. Presented at the 70th Congress of the International Pharmaceutical Federation (World Congress of Pharmacy and Pharmaceutical Sciences 2010), Lisbon, Portugal.
82. **Gray AL** (2010). *The new WHO Model List of Essential Medicines for Children*. Presented at the 26th International Pediatric Association Congress of Pediatrics, Johannesburg.
83. **Gray A, Holloway K** (2010). *Is WHO's Essential Medicines List contributing to rational medicines use in developing countries?* Presented at the 16th World Congress of Basic and Clinical Pharmacology, Copenhagen, Denmark.
84. **Boshoff R, Gray AL** (2010). *The dog didn't eat my homework, it was run over by a train*. A PEARL presentation at the 24th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Drakensberg.
85. **Gray AL** (2009). *Basel Statements on the Future of Hospital Pharmacy - moving from global consensus to local action*. Presented at the China-Japan Pharmacy International Forum, Beijing, China.
86. **Gray AL** (2009). *Basel Statements on the Future of Hospital Pharmacy - the Strategic Moment*. Presented at the China-Japan Pharmacy International Forum, Beijing, China.
87. **Gray AL** (2009). *Model List of Essential Medicines for Children – WHO strategy for rational use of medicines*. Presented at the 3rd Brazilian Congress on Rational Use of Medicines, Fortaleza, Brazil.
88. **Gray AL** (2009). *Group practice*. Presented at the Joint Independent Pharmacy Conference, Durban.
89. **Gray AL** (2009). *The role of therapeutic drug monitoring in HIV management*. Presented at the Southern African HIV Clinicians' Society, KZN branch, Durban.
90. **Gray AL** (2009). *Eliminating unnecessary and inappropriate antimicrobial use – the role pharmacists can play*. Presented at the FIP/WHO World Alliance on Patient Safety Joint Symposium, 69th Congress of the International Pharmaceutical Federation (World Congress of Pharmacy and Pharmaceutical Sciences 2009), Istanbul, Turkey.
91. **Gray AL** (2009). *The Global Conference on the Future of Hospital Pharmacy – from international consensus to local action*. Presented at the 10th Commonwealth Pharmacists' Association Conference, Accra, Ghana.
92. **Gray AL** (2009). *Generic vs. therapeutic substitution – differences*. Presented at the South African Society of Anaesthesiology, Bloemfontein.
93. **Gray AL** (2009). *Collaborative practice – more than just task shifting*. Presented at the Pharmaceutical Society of South Africa Conference, Spier.
94. **Gray AL** (2009). *WHO List of Essential Medicines for Children – challenges and opportunities*. Presented at the 1st International Symposium for Pediatric Pharmacy and Pharmacology, American College of Clinical Pharmacy/ European Society for Clinical Pharmacy International Congress on Clinical Pharmacy, Orlando FL, USA.
95. **Gray AL** (2009). *The Global Conference on the Future of Hospital Pharmacy*. Presented at the World Health Organization, Geneva, Switzerland.
96. **Gray AL** (2009). *The Global Conference on the Future of Hospital Pharmacy*. Presented at the 22nd Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Drakensberg.
97. **Gray AL** (2009). *Generic medicines – where are the safeguards?* Presented at the 28th Annual National Conference of the South African Society of Anaesthesiologists, Durban.
98. **Gray AL** (2009). *Nurse prescribing and dispensing – an enabling framework*. Presented at the Nurses' Response to the Goals of the National Strategic Plan, Jhpiego Workshop, Cape Town.
99. **Gray AL** (2009). *ARV-associated lactic acidosis - the challenge for the pharmacist*. Presented at the SAAHIP KwaZulu-Natal Coastal branch, Durban.
100. **Gray AL** (2008). *The Global Conference on the Future of Hospital Pharmacy*. Presented at the 43rd Mid-year Clinical Meeting of the American Society of Health-system Pharmacists, Orlando FL, USA.
101. **Gray AL** (2008). *Generic vs. therapeutic substitution – differences*. Presented at the South African Society of Anaesthesiology, Pretoria.
102. **Gray AL** (2008). *The South African experience with regulating medicine prices*. Presented at the IXth World Conference on Clinical Pharmacology and Therapeutics, Québec, Canada.
103. **Gray AL** (2008). *Issues of paediatric pharmacotherapy in Africa*. Presented at the Pediatric Pharmacology Satellite Conference, IXth World Conference on Clinical Pharmacology and Therapeutics, Toronto, Canada.
104. **Gray AL** (2008). *Generic substitution – opportunities and pitfalls*. Presented at the 17th Pharmaceutical Society of Namibia Conference, Windhoek, Namibia.
105. **Gray AL** (2008). *Nurse prescribing and dispensing - second-rate care or opportunity?* Presented at the 4th Public Health Association of South Africa Conference, Cape Town.

106. **Gray AL** (2008). *Nurse prescribing and dispensing – ART +*. Presented at the Democratic Nurses Organisation of South Africa and Health Systems Trust colloquium, Pretoria.
107. **Gray AL** (2008). *Opposition to generic substitution – countering the arguments*. Presented at the SAAHIP KwaZulu-Natal Coastal branch, Durban; Netcare Group, Durban.
108. **Gray AL** (2006/7). *Generic and therapeutic substitution*. Presented at the MediClinic pharmacy and nursing managers' conference, Pretoria; Medi-Clinic staff and Antibiotic Review Group, Panorama Hospital, Cape Town; MediClinic staff in Welkom, Bethlehem and Newcastle.
109. **Gray AL** (2006). *Strategic priorities in Health*. Presented at the Pharmaceutical Society of South Africa Conference, Boksburg.
110. **Gray AL** (2006). *The political economy of ART*. Presented at the Nelson R Mandela School of Medicine Students' Clinical Conference, Durban.
111. **Gray AL** (2006). *Medicines Amendment Bill –the medicines pricing issue*. Presented at the KwaZulu-Natal Progressive Primary Healthcare Network, Durban.
112. **Ducasse G, Gray A, Whittaker S** (2006). *Using technology to avoid medication errors in the neonatal intensive care setting – a continuous quality improvement project*. Presented at the 27th Annual Congress of the Critical Care Society of Southern Africa, Johannesburg.
113. **Mathibe LJ, Harris J, Gray A** (2006). *Student nurses' perceptions of administration charts for injectable antibiotics*. Tau Lambda Nursing Chapter International Conference, Durban.
114. **Gray AL** (2005). *Human resources in hospital pharmacy – problems in the African continent*. Presented at the 65th Congress of the International Pharmaceutical Federation (World Congress of Pharmacy and Pharmaceutical Sciences 2005), Cairo, Egypt.
115. **Gray AL** (2005). *Generic medication: safeguards and potential*. Presented at MediClinic, Bloemfontein.
116. **Gray AL** (2005). *The policy-law-practice nexus – lessons from 2005*. Presented at the Health Partners/KwaZulu-Natal Managed Care Coalition, Durban.
117. **Gray AL** (2005). *Better compliance and adherence*. Presented at the Asthma for Africa Conference, Johannesburg.
118. **Gray AL** (2005). *Medicine pricing – a theoretical overview*. Presented at the 25th Islamic Medical Association Convention, Durban.
119. **Gray AL** (2005). *Reaching all who need treatment - South African experience. HIV/AIDS in Southern Africa: spread of the disease, treatment strategies and perspective for the future*. Presented at the Evangelische Kirchentag 2005, Hannover, Germany; BUKO Pharma-Kampagne, Marburg and Krefeld, Germany.
120. **Gray AL** (2005). *HIV and AIDS in South Africa – where are we now?* Presented at the School of Public Health, Bielefeld University, Germany.
121. **Gray AL** (2005). *HIV/AIDS and politics in South Africa: AIDS-Politik in Südafrika: Probleme und Erfolge*. School of Medicine "AIDS-Woche". Presented at the Friedrich Schiller University, Jena, Germany
122. **Gray AL** (2005). *Prices and policy – the forces in the hospital sector*. Presented at AstraZeneca and MediClinic Holdings, Cape Town.
123. **Gray AL** (2005). *ARV interactions – a major role for the pharmacist*. Presented at the SAAHIP KwaZulu-Natal Coastal branch, Durban.
124. **Gray AL** (2005). *Regulating the pharmacy sector*. AIDS Law Project and Treatment Action Campaign. Medicines, Rights and the Rule of law – the Struggle for Access to Health Care in South Africa, Johannesburg.
125. **Gengiah T, Upfold M, Gray A.** (2005). *Providing pharmaceutical services to an ARV treatment programme: challenges in a rural setting*. Presented at the 2nd South African National AIDS Conference, Durban.
126. **Boshoff R, Gray AL** (2005). *Section 22A(6)(h)(i) of the Medicines Act – a lame duck?* Presented at the 19th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Wilderness.
127. **Gray AL** (2004). *Professional remuneration in pharmacy*. Presented at Sovereign Health and Aspen Pharmacare, Durban.
128. **Gray AL** (2004). *HIV and AIDS in South Africa – where are we now?* Presented at the South African Association of Pharmaceutical Wholesalers Conference, Kleinmond.
129. **Gray AL** (2004). *Antiretrovirals and drug interactions*. Presented at the SAAHIP KwaZulu-Natal Inland branch, Pietermaritzburg.
130. **Gray AL** (2004). *ABC of PK/PD – focus on ARVs*. Presented at the Medicine Update, Durban.
131. **Gray AL** (2004). *The wheezing infant – review of the evidence*. Presented at the South African Thoracic Society Congress, Durban.

132. **Gray AL** (2004). *PK/PD in the ICU – focus on the aminoglycosides*. Presented at the Critical Care Congress, Durban
133. **Gray AL** (2004). *Generic substitution – what’s so scary?*. Presented at the Pharmaceutical Society of South Africa, Southern Gauteng branch, Johannesburg.
134. **Gray AL** (2004). *Medicine pricing – background and options*. Presented at the Pharmaceutical Society of South Africa Conference, Port Elizabeth.
135. **Gray AL** (2004). *Drugs, trade and HIV in Africa*. Presented at the 2nd African Conference on Social Aspects of HIV/AIDS Research, Cape Town.
136. **Gray AL** (2004). *Nurse prescribing and dispensing – 2004*. Presented at the Community Health Nurses Association, Durban.
137. **Gray AL** (2004). *Medicines access, pricing and policy*. Presented at Sovereign Health, Durban and Cape Town.
138. **Gray AL** (2004). *Direct-to-consumer advertising of prescription medicines – evidence from the developing world?* Presented at the 64th Congress of the International Pharmaceutical Federation (World Congress of Pharmacy and Pharmaceutical Sciences 2004), New Orleans, USA.
139. **Gray AL**, Essack SY (2004). *Methods for AMR surveillance in communities – lessons from the Durban site*. Presented at the 2nd International Conference on Improving Use of Medicines, Chiang Mai, Thailand.
140. **Gray AL**, Essack SY, Deedat F, Pillay T, van Maasdyk J, Holloway K, Sorensen TL, Sturm AW (2004). *Antimicrobial use and resistance surveillance pilot project – lessons from the Durban site*. Presented at the 2nd International Conference on Improving Use of Medicines, Chiang Mai, Thailand.
141. **Gray AL**, Essack SY, Deedat F, Pillay T, van Maasdyk J, Sturm AW (2004). *Developing a method for antimicrobial use and resistance surveillance – Durban pilot project*. Presented at the 18th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Drakensberg.
142. **Raftesath BE**, Gray AL (2004). *Chronic medicine prescribing in the elderly – there is room for improvement*. Presented at the 18th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Drakensberg.
143. **Gray AL** (2003). *Medicines Act – implications for medical practice*. Presented at Northmed Medical Management, Umhlanga Rocks.
144. **Gray AL** (2003). *Medicines-related law – what’s new post 2 May 2003*. Presented at Sovereign Health, Durban
145. **Gray AL** (2003). *Medicines Act – update and context*. Presented at the Pharmaceutical Society of South Africa, KwaZulu-Natal Coastal and Inland branches, Durban, Richards Bay and Pietermaritzburg.
146. **Gray AL** (2003). *Medicines Law in 2003*. Presented at the Nelson R Mandela School of Medicine Students’ Clinical Conference, Durban
147. **Botha J**, Gray A, McLean M (2003). *A new and innovative post -graduate programme in Clinical Pharmacology*. Presented at the Association for Medical Education in Europe (AMEE) Conference, Bern, Switzerland.
148. **Monticelli F**, Gray A, Day C (2003). *HIV/AIDS information resources – showcasing drug-related aspects*. Presented at the Health Informatics in Africa (HELINA) Conference, Johannesburg.
149. **Gray AL** (2003). *Antimicrobial resistance in developing countries*. Presented at the 63rd Congress of the International Pharmaceutical Federation (World Congress of Pharmacy and Pharmaceutical Sciences 2003), Sydney, Australia.
150. **Gengiah T**, Botha J, Gray A, Bhagwanjee S, Muckart D, Kleinschmidt I (2003). *Retrospective analysis of the use of continuous infusion furosemide in critically ill patients with oliguric acute renal failure*. Presented at the 37th Annual Conference of the South African Pharmacology Society, Stellenbosch.
151. **Chetty R**, Gray A (2003). *Inappropriate prescribing in the elderly – lack of benefit from an Essential Medicines List?* Presented at the 37th Annual Conference of the South African Pharmacology Society, Stellenbosch.
152. **Gray A**, Bannenberg W (2003) *Antiretroviral procurement options in South Africa – negotiating the minefield*. Presented at the South African National AIDS Conference, Durban.
153. **Gray A**, Harries K, Mathibe L (2003). *Concomitant TB and HIV treatment – more questions than answers*. Presented at the South African National AIDS Conference, Durban.
154. **Gray AL** (2003). *The trajectory of medicines legislation in South Africa*. Presented at Pharmaceuticals 2003, Cape Town.
155. **Day C**, Gray A (2003). *Tracking health-related indicators: possibilities & limitations*. Presented at the Public Health 2003 Conference, Cape Town.

156. **Mathibe LJ**, Botha JH, Szpak WM, Gray AL (2003). *A comparison of two different antiemetic regimens in cancer patients receiving moderately emetogenic chemotherapy*. Presented at the 17th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Drakensberg.
157. **Gray A**, Matsebula T, Blaauw D, Schneider H, Gilson L (2003). *Policy change in a context of transition: analysis of the national drug policy process in South Africa*. Presented at the 17th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Drakensberg.
158. **Gray AL** (2002). *How the pharmaceutical industry hinders access to essential drugs in poor countries – a South African perspective*. BUKO Pharma-Kampagne, Tübingen, Herrenberg, Munich, Heidelberg, Zell Oberhamersbach and Stollberg, Germany.
159. **Gray AL** (2002). *Legislative update 2002*. Presented at the SAAHIP mini-conference, Durban.
160. **Gray AL** (2002). *Legislative challenges in Pharmacy*. Presented at the South African Pharmaceutical Students Federation Conference, Durban.
161. **Gray AL** (2002). *Legislative challenges in Pharmacy*. Presented at the 22nd Islamic Medical Association Convention, Durban.
162. **Gray AL** (2002). *Generics – policy, legal, ethical, clinical and economic aspects*. Presented at the Novartis Managed Health Care Forum, Johannesburg.
163. **Gray AL** (2002). *How the pharmaceutical industry hinders access to essential drugs in poor countries – a South African perspective*. Presented at the Patents, Profits and AIDS – International Conference, Bad Boll, Germany.
164. Botha J, Gray A, **McLean M** (2002). *An innovative Masters in Clinical Pharmacology programme equips health care professionals to evaluate evidence and use medicines rationally*. Presented at the Health Professions Education International Conference, Bloemfontein.
165. **Gray A** (2002). *Understanding actors, contexts and processes*. Presented at the African Pharmaceutical Congress 2002, Midrand.
166. **Gray A**, Matsebula T, Blaauw D, Schneider H, Gilson L (2002). *Analysis of the drug policy process in South Africa*. Presented at the 62nd Congress of the International Pharmaceutical Federation (World Congress of Pharmacy and Pharmaceutical Sciences 2002), Nice, France.
167. **Gray AL**, Khan R, Sallet J-P (2002). *Community-level model of Pharmaceutical Care – pointers from South Africa*. Presented at the 62nd Congress of the International Pharmaceutical Federation (World Congress of Pharmacy and Pharmaceutical Sciences 2002), Nice, France.
168. **Gray A** (2002). *Direct-to-consumer advertising – pros and cons*. Presented at the 10th South African Pharmaceutical Summit (Pharmecon Conference 2002), Midrand. **Gray AL**, Sallet J-P (2002). *Does poor quantification impact on prices?* Presented at the 16th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Drakensberg.
170. **Raftesath BE**, Gray AL (2002). *Stimulant prescribing in the private sector – an area of concern?* Presented at the 16th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Drakensberg.
171. Khan R, Sallet J-P, **Gray AL** (2002). *Implementing district-based pharmaceutical services in a metropolitan area – data needs for planning*. Presented at the 16th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Drakensberg.
172. **Mestry K**, Smit J, McFadyen M, Mqhayi M, Gray AL, Morroni C, Connolly C (2001). *Who should supply and who should receive Emergency Contraception: opinions of rural and urban primary health care providers and clients*. Presented at the 7th Reproductive Health Research Priorities Conference, Drakensberg.
173. **Gray A** (2001). *Developing leadership to improve hospital pharmacy practice in South Africa*. Presented at the 61st Congress of the International Pharmaceutical Federation (World Congress of Pharmacy and Pharmaceutical Sciences 2001), Singapore.
174. **Gray A** (2001). *Identifying structural barriers to providing quality pharmaceutical care at district level*. Presented at the 15th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Knysna.
175. **Gray A**, Sallet J-P. (2001) *Integrating data from different sources to create management information for district pharmacists*. Presented at the 15th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Knysna.
176. **Gray AL**, Smit JA, McFadyen ML (2001). *Counting the costs: should depot medroxyprogesterone acetate and norethisterone oenanthate both be on the EDL?* Presented at the 15th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Knysna.
177. **Gray A** (2000). *Making antiretrovirals available in resource-poor settings*. Presented at the XIIIth International AIDS Conference, Durban.

178. **Gray A** (2000). *Public-private partnerships: problems and pitfalls*. Presented at the Pharmaceutical Society of South Africa Conference, Durban.
179. **Gray A** (2000). "*Public-private partnerships in Pharmacy*" Presented at the Pharmaceutical Society of South Africa, Northern Cape Branch, Kimberley.
180. **McFadyen L**, Smit J, Gray A, Mestry K (2000). *Emergency contraception: legal impediments to increased accessibility in South Africa*. Presented at the Joint Meeting of the VIIth World Conference on Clinical Pharmacology and Therapeutics & 4th Congress of the European Association of Clinical Pharmacology and Therapeutics, Florence, Italy.
181. **Smit J**, McFadyen L, Gray A, Zuma K (2000.) *A community-based survey of injectable contraceptive utilization in rural South Africa: patterns of use and experience of side effects*. Presented at the Joint Meeting of the VIIth World Conference on Clinical Pharmacology and Therapeutics & 4th Congress of the European Association of Clinical Pharmacology and Therapeutics, Florence, Italy.
182. **Smit J**, Gray A, McFadyen L (2000). *Cost implications of injectable contraceptive utilization patterns in South Africa*. Presented at the Joint Meeting of the VIIth World Conference on Clinical Pharmacology and Therapeutics & 4th Congress of the European Association of Clinical Pharmacology and Therapeutics, Florence, Italy.
183. **Day C**, Gray A (2000). *Drugspeak" on the line: how long is a piece of string?* Presented at the 14th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Hunters Rest (winner of the HHD Award for best podium presentation)
184. Pinyana B, Motwana E, Hall W, Orrell C, **Gray A** (2000). *Promoting rational drug use at district level: the Mt Frere experience*. Presented at the 14th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Hunters Rest.
185. **Gray AL** (1999). *Staffing district pharmaceutical services – some difficult choices lie ahead*. Presented at the 13th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Alpine Heath
186. **Gray AL** (1999). *District-based pharmaceutical services*. Presented at the Mpumalanga Province Pharmaceutical Services Conference, Warmbaths.
187. **Gray AL** (1999). *Who does what, where and when in district-based pharmaceutical services?*. Presented at the Northern Province Pharmaceutical Services Conference, Mopani Camp.
188. **Gray AL** (1999). *Medicines Regulatory Perspective – ECP*. Presented at the Africa Centre for Population Studies and Reproductive Health workshop on Emergency Contraception, Durban.
189. **Gray AL** (1999). *Private hospital pharmacy and the Law – change at last?*. Presented at the Afrox Healthcare Pharmacy Management Conference, Mt Grace.
190. **Gray AL** (1999). *Legal developments relevant to private hospital nursing*. Presented at the Afrox Healthcare Nursing Service Managers Conference, Durban.
191. **Gray AL**, Mielke BE, Taylor B (1999). *Private sector methyl dopa use as a measure of rational application of evidence*. Presented at the 13th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Alpine Heath.
192. **Mielke BE**, Taylor B and Gray AL (1999). *Can the private sector use thiazides any better?* Presented at the 13th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Alpine Heath.
193. Conry I, **Fitzpatrick RK**; Gray A; Hattingh HL; Putter SJ; Summers, RS (1999). *Staffing norms for public sector hospitals*. Presented at the 13th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Alpine Heath.
194. **Gray AL** (1998). *Go Fly a Kite – it's the right time to do it!* Presented at the Health Systems Trust Research Conference, Durban.
195. **Gray AL** (1998). *District-based pharmaceutical services – what does it mean?* Presented at the SAAHIP KwaZulu-Natal Inland Branch, Pietermaritzburg.
196. **Gray AL**, Smit JA (1998). *District-based pharmaceutical services: the scale of the challenge*. Presented at the 12th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Mount Amanzi.
197. **Mielke BE**, White MI, Gray AL (1998). *Pharmacy services in an Academic Health Service Complex – possible pointers from the Western Cape perspective*. Presented at the 12th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Mount Amanzi.
198. **Gray AL**, Mielke BE, White MI (1998). *Academic Health Service Complexes: what will the pharmacy academics do?* Presented at the 12th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Mount Amanzi.

199. **Gray AL** (1997). *A pox on the dose: pharmacodynamics and pharmacokinetics in the critically ill*. Presented at the 19th Annual Congress of the Critical Care Society of Southern Africa, Durban
200. **Gray AL, Gordan PA, Smit JA, Smit DP, Turini B, Stavie RB** (1997). *The influence of social context on community participation in CBHPE projects: a Londrina-Durban contrast*. Presented at the International Conference on Involvement of Communities in Health Professions Education: Challenges, Opportunities and Pitfalls, Mexico City, Mexico.
201. **Gray AL, Seneque MB, Smit JA** (1997). *An epistemology for Pharmacy Practice - sine qua non or non sequitur?* Presented at the 31st Annual Conference of the South African Pharmacology Society, Karos Mont aux Sources.
202. **Smit JA, Gray AL** (1997). *A problem-oriented approach to Pharmacy Practice teaching within the context of an emerging health district*. Presented at the 31st Annual Conference of the South African Pharmacology Society, Karos Mont aux Sources.
203. **Gray AL, Smit JA** (1997). *Clinical training issues in a primary care setting - pointing the way to the academic health service complex*. Presented at the Community-Based Education Conference, South African Network of Community Partnerships in Health Personnel Education, Durban.
204. **Smit JA, Gray AL** (1997). *Using an emerging health district as the context for a problem-oriented approach to Pharmacy Practice teaching*. Presented at the Community-Based Education Conference, South African Network of Community Partnerships in Health Personnel Education, Durban.
205. **Gray AL, Day C, Mlisana K** (1997). *Promoting the rational use of drugs: a demonstration project using electronic communication*. Presented at the 11th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Port Elizabeth.
206. **Essack SY, McFadyen ML, Pillay B, Gray AL** (1997). *Beta-lactam antibiogram for South African strains of *Klebsiella pneumoniae*: implications for practice*. Presented at the 11th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Port Elizabeth.
207. **Ratmtoola H, Gray AL** (1997). *Transition to managed health care: a view from the trenches*. Presented at the 11th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Port Elizabeth.
208. **Day C, Gray AL** (1997). *Exploring AIDS information needs and delivery: the use of electronic communications*. Presented at the 11th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Port Elizabeth.
209. **Gray AL, Smit JA** (1997). *The proposed personnel assessment system for the public sector: a social validity analysis*. Presented at the 11th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Port Elizabeth.
210. **Gray AL, Smit JA** (1996). *Scenarios for pharmacy in the District Health System - the low road or the high road?* Presented at the 4th International Conference of the Community Health Association of Southern Africa, Sun City.
211. **Gray AL, Bhana A, Ibrahim N, Naidoo UA, Narainduth S, Sheik M.** (1996). *Formulary management tools for the district pharmacist*. Presented at the 4th International Conference of the Community Health Association of Southern Africa, Sun City.
212. **Gray AL, Botha JH** (1996). *A model based approach to estimating maintenance doses in children on combination anticonvulsants*. Presented at the 12th Congress of the Pan-African Association of Neurological Sciences, Durban.
213. **Gray AL** (1996). *Sequential antibiotic therapy*. Presented at the Department of Medical Microbiology (University of Natal), Department of Surgery (Addington Hospital) and SAAHIP, Natal Coastal Branch.
214. **Gray AL** (1996). *Introduction to the National Drug Policy*. Presented at the Health Department, Western Council of the Durban Metropolitan Council.
215. **Gray AL, Smit JA** (1996). *Scenario building - leading Pharmacy into the District Health System*. Presented at the 10th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Wilderness.
216. **Gray AL, Bhana A, Ibrahim N, Naidoo UA, Narainduth S, Sheik M.** (1996). *Formulary management tools for the district pharmacist*. Presented at the 10th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Wilderness.
217. **Day C, Gray AL** (1996). *Management information, computers and Pharmacy: a private-public sector contrast*. Presented at the 10th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Wilderness.
218. **Gray AL, Smit JA, Dangor CM** (1995). *The patient as the focus of Pharmacy education*. Presented at the International Conference on Quality Assessment in Health Professions Education (with special emphasis on social accountability), Manila, Philippines.

219. **Smit JA**, Gray AL, Bhagwanjee AM, Haffajee MR (1995). *Capacity assessment of a Faculty of Health Sciences: implications for regional resource rationalisation*. Presented at the International Conference on Quality Assessment in Health Professions Education (with special emphasis on social accountability), Manila, Philippines.
220. **Smit JA**, Chetty DJ, Dangor CM, Essack SY, Gray AL (1995). *Pharmacy curricula in South Africa: radical transformation and challenges*. Presented at the International Symposium on the Role of the University in Health Research for Development, Madras, India.
221. **Bhagwanjee A**, Smit JA, Gray AL (1995). *Building institutional capacity for ENHR in developing countries: some experiences from a South African perspective*. Presented at the International Symposium on the Role of the University in Health Research for Development, Madras, India.
222. **Gray AL** (1995). *Practical pharmacokinetics in the ICU*. Presented at the Critical Care Refresher Course, Durban.
223. **Gray AL** (1995). *Faculty transformation: the Health Sciences experience*. Presented at the Modularization Workshop, University of Durban-Westville
224. **Botha JH**, Gray AL, Miller R (1995). *Population clearance of carbamazepine in children on mono and polytherapy*. Presented at the 30th Annual Congress of the Pharmacological Society of Southern Africa, Bloemfontein.
225. **Gray AL**, Gray RA (1995). *Assessment of drug allergy reporting in a private hospital*. Presented at the 9th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Club Mykonos, Langebaan.
226. **Gray AL** (1994). *Antibiotics and STD*. Presented at the Sexually Transmitted Diseases Seminar, KwaZulu-Natal Department of Health, Pinetown
227. **Gray AL** (1994). *Planned progressive therapy - a case study*. Presented at the SAAHIP Natal Coastal Branch, Durban.
228. **Gray AL** (1994). *Rational drug use in PHC clinics*. Presented at the Durban City Health Department.
229. **Gray AL** (1994). *Influence of concomitant medication on valproate clearance in children*. Presented at the 15th Congress of the Academy of Pharmaceutical Sciences, Grahamstown.
230. **Botha J**, Gray A, Miller R (1994). *Phenobarbitone clearance values for South African children*. Presented at the XIIth International Congress of Pharmacology, Montreal, Canada.
231. **Botha J**, Gray A, Miller R (1994). *Determination of population phenobarbitone clearance values for children using routine clinical data*. Presented at the 29th Congress of the Pharmacological Society of Southern Africa, Cape Town.
232. **Gray AL** (1993). *Primary Health Care Medicines - an Update*. Presented at the Natal Professional Community Nurses Society, Durban.
233. **Gray AL** (1993). *Drug use evaluation - closing the loop*. Presented at the 7th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), Somerset-West. (Best presentation award).
234. **Gray AL** (1992). *Drug use evaluation - Angiotensin converting enzyme inhibitors*. Presented at the University of Natal, Faculty of Medicine Grand Round.
235. **Gray AL** (1992). *Pharmaceutical Care - an attainable goal in our practice setting?* Presented at the 6th Annual Conference of the South African Association of Hospital and Institutional Pharmacists (SAAHIP), San Lameer.
236. **Gray AL** (1991). *Antibacterial drugs and the pharmacist*. Presented at the Plus Continuing Pharmacy Education Programme, Durban.
237. **Gray AL** (1991). *Pharmaceutical Care*. Presented at the SAAHIP Natal Inland Branch, Pietermaritzburg.
238. **Gray AL**, **Botha JH**, Moodley M, Bobat R (1990). *Development and evaluation of the first Therapeutic Drug Monitoring programme at King Edward VIII Hospital*. Presented at the 4th Faculty Research Day, Faculty of Medicine. University of Natal, Durban.
239. **Rauch AJ**, Gaffin SL, Welsh NH (1985). *Topical immunotherapy for Pseudomonas keratitis: use of antilipopolysaccharide plasma*. Presented at the 1st International Conference on Infection Control, Harrogate, United Kingdom.
240. **Gaffin SL**, Zanotti A, Jordaan JH, Welsh NH, Rauch A, Brock-Utne JG, Wells M, Lachman E (1984). *Anti-lipopolysaccharide antibodies successfully treated shock, radiation sickness, surface infections and septic abortions in animals*. Presented at the South African Physiology Society Congress, Durban.

POST-GRADUATE SUPERVISION / EXAMINATION

Current supervision

- 2020: Ms N Khoza (207504931). Master of Public Health candidate.
- 2019: Ms R Rooplal (9500072). *An analysis of the implementation of the Early Hearing Detection and Intervention Programme in public sector Audiology departments in KwaZulu-Natal.* Master of Public Health candidate.
- 2018: Ms Y Habibat Alimi. Doctor of Philosophy candidate (with Prof SY Essack and Prof C Stålsby Lundborg).
- 2018: Dr S Nakka David (218053990). Master of Pharmacy (Pharmacy Practice) candidate.
- 2018: Ms S Hlongwana (9600931). *Barriers and facilitators to the collection of Patient Medicine Parcels dispensed through the Centralised Chronic Medicine Dispensing and Distribution program at Prince Mshiyeni Memorial Hospital in 2017.* Master of Public Health candidate.
- 2018: Ms ZZ Nzuzo (200000374). *Patients' knowledge, attitudes, and practices regarding the Centralised Chronic Medication Dispensing and Distribution Programme.* Master of Public Health candidate.
- 2017: Dr N Khuzwayo (993214343). *Barriers to accessing third-line antiretroviral therapy in Primary Health Care settings in eThekweni District, KwaZulu-Natal, South Africa.* Master of Public Health candidate.
- 2016: Ms K Seedat (205503598). Master of Pharmacy (Pharmacy Practice) candidate.
- 2015: Ms V Ramdial (931345193). *The regulation of cosmetology in South Africa, with a focus on 'minimally invasive cosmetic procedures' (MICPs).* Doctor of Philosophy candidate (with Prof Y Vawda).
- 2015: Mr N Sibisi (214550094). *Challenges to the use of combination ART: a retrospective cohort study at ACTS Clinic.* Master of Pharmacy (Pharmacy Practice) candidate.

Past supervision

- 2020: Ms P Mahadeo (205511485). *Assessing eligibility for enrolment into the differentiated care program among patients receiving antiretroviral therapy within eThekweni public health facilities.* Master of Public Health, University of KwaZulu-Natal.
- 2019: Mr A Kuudzadombo. *Management and control of hypertension and associated co-morbidities in an ambulatory care setting – a medicines utilization review.* Master of Pharmacy (Pharmacy Practice), University of KwaZulu-Natal.
- 2018: Ms T Mafundikwa. *Knowledge, attitudes and practices of pharmacists in Harare regarding the reporting of adverse drug reactions.* Master of Pharmacy (Pharmacy Practice), University of KwaZulu-Natal.
- 2017: Ms Z Zondi. *Traditional medicine use in patients on antiretroviral therapy: a cross-sectional study at Thembaletu Wellness Centre, Northdale Hospital.* Master of Public Health (Medicines Management), University of KwaZulu-Natal.
- 2017: Ms S Govender. *Antibiotic prophylaxis in a primary level hospital: a medicines use evaluation to assess compliance in caesarean sections.* Master of Pharmacy (Pharmacy Practice) (*cum laude*), University of KwaZulu-Natal.
- 2017: Mr K van der Walt. *Clinical pharmacy services in South Africa and the factors hindering their progress.* Master of Pharmacy (Pharmacy Practice), University of KwaZulu-Natal.
- 2015: Mr I Joosub. *Cost minimization analysis of meropenem versus imipenem/ cilastatin in moderate to severe infections at a tertiary care hospital in Saudi Arabia.* Master of Pharmacy (Pharmacoeconomics), University of KwaZulu-Natal.
- 2014: Ms F Fyzoo. *Clinical outcomes and costs associated with the use of rituximab for the treatment of diffuse large B-cell lymphoma.* Master of Public Health, University of KwaZulu-Natal.
- 2014: Mr N Mthethwa. *Tuberculosis medicine consumption trends in the private health sector in South Africa.* Master of Public Health, University of KwaZulu-Natal.
- 2013: Ms N Chapi. *Challenges in the integration of municipal health services in the Umgungundlovu District Municipality, KwaZulu-Natal.* Master of Public Health, University of KwaZulu-Natal (with Dr C Blanchard).
- 2012: Dr MF Mahomed. *Assessment of knowledge of and attitudes towards health legislation among private family practitioners working in a defined geographical area.* Master of Public Health University of KwaZulu-Natal.
- 2011: Ms D Govender. *Primary school teachers' knowledge of asthma in Ugu North.* Master of Public Health, University of KwaZulu-Natal.

- 2008: Ms A Shaw. *The influence of pending legislation on drug advertising in South Africa*. Master of Clinical Pharmacology, University of KwaZulu-Natal.
- 2007: Ms E Nicolosi. *The potential for cost savings by extensively using generics for chronic conditions in South Africa*. Master of Business Administration, University of KwaZulu-Natal (with Ms G Manion)
- 2006: Ms S Podmore. *Use of hormone therapy (HT) and non-hormone therapy (NHT) for menopause in South Africa (2000 – 2005)*. Master of Clinical Pharmacology, University of KwaZulu-Natal (with Prof J Botha).
- 2006: Rev LJ Mathibe. *Nurses and students nurses' perceptions and use of antibiotic administration charts*. Master of Science (Evidence-based Health Care), University of Oxford (with Dr J Harris).
- 2004: Ms BE Raffesath. *Auditing prescribing patterns in elderly patients within a managed care setting*. Master of Pharmacy (*cum laude*), University of KwaZulu-Natal (with Dr J Smit).
- 2003: Ms T Gengiah. *Retrospective analysis of the use of continuous infusion furosemide in critically ill patients with oliguric acute renal failure*. Master of Clinical Pharmacology (*cum laude*), University of Natal (with Prof J Botha).
- 2003: Mr LJ Mathibe. *A comparison of two different antiemetic regimens in cancer patients receiving moderately emetogenic chemotherapy*. Master of Clinical Pharmacology, University of Natal.
- 2003: Ms R Chetty. *Auditing prescribing patterns in elderly patients within a public sector primary health care setting*. Master of Clinical Pharmacology, University of Natal.
- 1999: Mr A Suleman. *The effect of changing import regulations for pharmaceuticals on the South African economy*. Master of Pharmacy, University of Durban-Westville.

External and internal examiner

- 2019: Mr T Modau. *The availability of persons nominated for adverse drug reporting and associated challenges in Gauteng regional and district public hospitals*. Master of Science in Pharmacy Administration and Policy Regulation. University of the Western Cape.
- 2017: Mr R Thorpe. *The knowledge, attitudes and practices of South African-based runners regarding the use of pain alleviating medication during training and competition*. Master of Philosophy in Exercise and Sports Physiotherapy. University of Cape Town.
- 2016: Ms M Shrestha. *Exploring medicine procurement through the lens of the Basel Statements: a comparative study between Australia and Nepal*. Master of Philosophy (Pharmacy), University of Sydney, Australia.
- 2016: Ms JA Tymbios. *An evaluation of Western herbal complementary medicine labelling in South Africa, to determine whether the product labelling information complies with established herbal monographs and whether it meets local regulatory requirements*. Master of Science (Pharmacy Administration and Policy Regulation), University of the Western Cape.
- 2015: Ms S Ahmed-Hassen. *A cost analysis of the conventional culture method versus polymerase chain reaction testing for methicillin-resistant *Staphylococcus aureus* at a South African public hospital*. Master of Science (Medicine). University of the Witwatersrand.
- 2015: Ms A Tromp. *Co-morbidity of and treatment for irritable bowel syndrome, depression and anxiety in retirement village residents*. Master of Medical Science (Pharmacology), University of the Free State.
- 2014: Dr T Chirima. *Inappropriate antibiotic prescribing: a cross-sectional study in Swaziland*. Master of Science in Clinical Epidemiology, University of Stellenbosch.
- 2013: Ms TD Leong. *Rheumatologists' perceptions on the co-incidence of tuberculosis associated with TNF-inhibitors for the treatment of rheumatoid arthritis in South Africa*. Master of Science in Medicine (Pharmacotherapy), University of the Witwatersrand.
- 2013: Dr CH Vaughan-Williams. *Assessment of the therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated *Plasmodium falciparum* malaria in northern KwaZulu-Natal*. Master of Public Health, University of KwaZulu-Natal.
- 2011: Dr B Waning. *Innovative approaches to pharmaceutical policy research in developing countries: the view thru a market lens*. Doctor of Philosophy, University of Utrecht, The Netherlands.
- 2011: Ms KL Nixon. *Pre-treatment preparation and loss-to-care of adults living with HIV from an antiretroviral therapy clinic in Durban, KwaZulu-Natal*. Master of Public Health, University of KwaZulu-Natal.
- 2010: Mr TA Chizanga. *The Impact of HAART on sexuality and medicine taking behaviours among people living with HIV/AIDS in Grahamstown*. Master of Pharmacy, Rhodes University.

- 2009: Dr C Narasimooloo. *Assessment of pain and adequacy of its treatment in adult patients with human immunodeficiency virus (HIV) related disease*. Master of Family Medicine, University of KwaZulu-Natal.
- 2008: Dr EJ Anyachebelu. *Impact of delayed introduction of sulfadoxine-pyrimethamine and artemeter-lumefantrine on malaria epidemiology in KwaZulu-Natal, South Africa*. Master of Public Health, University of KwaZulu-Natal.
- 2007: Ms O Taylor. *Affordability of medicines for patients with diabetes attending University of Nigeria Teaching Hospital (UNTH), Enugu*. Master of Public Health, University of the Western Cape.
- 2003: Mr S Morries. *Survey on retail prices of prescription drugs in Uganda: an inter-regional comparison*. Master of Public Health (Health Economics) dissertation, University of Cape Town.
- 2002: Ms A Mutsago. *Pharmaceutical pricing: assessing the impact of factors influencing HIV/AIDS and AIDS related medicine prices in Zimbabwe*. Master of Commerce (Economics) dissertation, University of Cape Town.
- 2001: Ms LD Woodin. *Pharmaceutical company mergers and the regulatory process in South Africa*. Master of Pharmacy treatise, University of Port Elizabeth.
- 1996: Ms FA Moola. *Antipsychotic drug use in Black patients in a peri-urban KwaZulu-Natal hospital*. Master of Medical Science dissertation, Medical University of Southern Africa (MEDUNSA).

INVITED REVIEWER AND EDITORIAL BOARDS

- Associate editor: South African Pharmaceutical Journal
- Section editor: Journal of Pharmaceutical Policy and Practice
- Editorial board member: International Journal of Clinical Pharmacy
Health Systems and Reform
BMC Health Services Research (Associate Editor)
- Editorial advisory board: GaBI (Generics and Biosimilars Initiative) Journal
South African Health Review
- Editorial Sub-Committee
for Guideline Review: South African Medical Journal
- Journal reviewer: African Health Sciences
African Journal of AIDS Research
African Journal of Primary Health Care and Family Medicine
African Studies
American Journal of Health-System Pharmacy
Archives of Diseases in Childhood
Basic & Clinical Pharmacology & Toxicology
BMJ Open
BMC Health Services Research
BMC Medical Education
BMC Pharmacology and Toxicology
British Medical Journal
Bulletin of the World Health Organization
Children
Cochrane Collaboration
Cost Effectiveness and Resource Allocation
Critical Public Health
Developing World Bioethics
Education for Health
Eastern Mediterranean Health Journal
European Journal of Pediatrics
Expert Opinion on Investigational Drugs

Expert Opinion on Pharmacotherapy
 Expert Review of Clinical Pharmacology
 Frontiers in Pharmacology
 GaBI (Generics and Biosimilars Initiative) Journal
 Global Health Action
 Globalization and Health
 Health Policy
 Healthcare Policy—Politiques de Santé
 Health Policy and Planning
 Health Research Policy and Systems
 Health SA Gesondheid
 Indian Journal of Medical Research
 International Journal of Clinical Pharmacy (formerly Pharmacy World and Science)
 International Journal of Infectious Diseases
 International Journal of Pharmacy Practice
 International Journal of Tuberculosis and Lung Disease
 Inquiry, The Journal of Health Care Organization Provision and Financing
 Journal of Antimicrobial Chemotherapy
 Journal of Clinical Pharmacy and Therapeutics
 Journal of Clinical Pharmacology
 Journal of Clinical Trials and Patenting
 Journal of Evidence-based Medicine
 Journal of Medical Economics
 Journal of Pain and Symptom Management
 Journal of Pharmaceutical Health Services Research
 Journal of Pharmaceutical Policy and Practice (formerly Southern Med Review)
 Journal of Public Health and Epidemiology
 Journal of the International AIDS Society
 Lancet Infectious Diseases
 Medicina
 Pediatric Drugs
 Pharmacoepidemiology and Drug Safety
 PLoS Medicine
 PLoS ONE
 Recent Patents on Anti-Infective Drug Discovery
 Research in Social and Administrative Pharmacy
 Social Science and Medicine
 South African Medical Journal
 South African Pharmaceutical Journal
 Tropical Medicine and International Health

Funders: Health Systems Trust
 National Research Foundation
 Medical Research Council
 UNITAID
 Swiss National Science Foundation
 Irish Research Board
 UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research,
 Development and Research Training in Human Reproduction (HRP) Research Project
 Review Panel (RP2)

Series Co-editor (with Helle Håkonsen, Fatima Suleman and Zaheer-Ud-Din Babar) of the Journal of
 Pharmaceutical Policy and Practice series on access to medicines, pricing, generics, and biologics (November 2018)

Major Reports: United Nations Millennium Project. Task Force on HIV/AIDS, Malaria, TB and Access
 to Essential Medicines. Working Group on Essential Medicines Report (Leach B, Paluzzi
 JE, Munderi P. Prescription for healthy development: increasing access to medicines.
 2005)

INVITED MODERATOR / EXTERNAL EXAMINER

2019:	External examiner for the Pharmaceutical Policy and Management module, MPH course, University of the Western Cape
2016-2018:	External examiner for the Pharmacy Practice 4 (Pharmacy Law) component, BPharm course, Rhodes University
2015-2016:	External examiner for the Oliver Tambo Fellowship programme (Post-graduate Diploma in Health Management; Working in complex health systems module; and Leading health system improvement module), Department of Public Health and Family Medicine, University of Cape Town
2011-2013:	External examiner for the Pharmacology component, BPharm course, University of the Witwatersrand.
2011-2013:	External examiner for the Oliver Tambo Fellowship programme (Post-graduate Diploma in Health Management; Managing health policy implementation module), Department of Public Health and Family Medicine, University of Cape Town
1997-1999/2005-10:	Moderator (1997/2005/6) and Examiner (1998/9/2006-10) for the South African Pharmacy Council in Laws Pertaining to Pharmacy Practice (written by foreign graduates)
1996-1999:	Moderator (1996/7) and Examiner (1998/9) for the Pharmacy Council's Pharmacists' Assistant Examination in Pharmacy Law
1997-1999:	Moderator for the University of Port Elizabeth final year examination in Pharmacy Practice
1996-1997:	Moderator for the Pre-Registration Evaluation, Interim Pharmacy Council of South Africa

COURSES/ WORKSHOPS PRESENTED

2017:	<i>Understanding and implementing the new General Medicines Regulations</i> , PharmaTraining and Generic and Biosimilar Medicines Southern Africa, Midrand.
2017:	<i>Third Medicines Utilisation Research in Africa Group workshop and symposium</i> , with the University of Namibia and Karolinska Institute, Windhoek, Namibia.
2017:	<i>Brush Up on Naming and Scheduling Matters</i> , PharmaTraining, Johannesburg.
2016:	<i>Second Medicines Utilisation Research in Africa Group workshop and symposium</i> , with the University of Botswana and Karolinska Institute, Gaborone, Botswana.
2015:	<i>First Medicines Utilisation Research in Africa Group workshop and symposium</i> , with the University of Botswana and Karolinska Institute, Gaborone, Botswana.
2011:	<i>SADC Flagship Course on Pharmaceutical Reform</i> . Southern African Regional Programme on Access to Medicines and Diagnostics (SARPAM), with the University of the Western Cape, and Professors Michael Reich and Marc Roberts (Harvard School of Public Health). Cape Town.
2011:	<i>Evidence, money & drug selection: a short course in pharmacoconomics</i> . World Health Organization; Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology; Republic of Ghana Ministry of Health; Ghana College of Physicians and Surgeons; Accra, Ghana.
2010:	<i>Criteria and Policies for the Evaluation of Proprietary Names and Scheduling</i> . South African Association of Pharmacists in Industry/Medicines Control Council workshop on the South African Common Technical Document, Pretoria.
2010-2012:	<i>Drug registration: data exclusivity and linkages</i> . Human Rights and Access to Medicines course, Centre for Human Rights, University of Pretoria (in conjunction with the Program on Information Justice and Intellectual Property, American University Washington College of Law).
2009:	<i>Paediatric dosing</i> . 3rd Brazilian Congress on Rational Use of Medicines, Fortaleza, Brazil.
2006/7:	<i>Information, pharmacovigilance and patient safety – approaches to data collection, analysis, dissemination and use</i> . International Pharmaceutical Federation, Pan-American Health Organization and the Uppsala Monitoring Centre, Salvador da Bahia, Brazil and Beijing, China.

- 2006: *The National Drug Policy – 10 years on.* Pharmaceutical Society of South Africa Conference, Boksburg.
- 2005-2007: *Selection* module for the Supply Chain Management of HIV/AIDS Medicines and Supplies courses, IDA Solutions, Pretoria.
- 2003/2005: Various modules on the “*Drug and Therapeutics Committee*” courses. Management Sciences for Health, Durban, Cape Town and Pietermaritzburg.
- 2003: *The South African Health System – structured for equity?* Pharmaceutical Society of South Africa Conference, Port Elizabeth.
- 2002: *HIV/AIDS in South Africa.* Pharmaceutical Society of South Africa Conference, Kopanong.
- 2002: *Draft National Health Bill – implications for hospital and institutional pharmacists.* SAAHIP Conference, Drakensberg.
- 2000/1/2/4/5: *Drug management for Health Service Managers* module in the Oliver Tambo Fellowship Programme, Department of Community Health, University of Cape Town.
- 2000-2009: *Drug Policy/Drug Management for Health Managers*, Principles of Health Systems and Health Economics/ Health Systems Operational Management modules. Advanced Health Management Programme/ Diplomas in Health Systems Management and Cost-effective Health Management/ Masters in Public Health, School of Health Systems and Public Health, University of Pretoria.
- 1999: *Drug Management for District Health Systems.* Eastern Seaboard Association of Tertiary Institutions Public Health Initiative Summer and Winter Schools (with J Smit, F Suleman, H Moller).
- 1998: *Human Resources for Pharmacy – making the future happen.* Presented on behalf of the South African Association of Hospital and Institutional Pharmacists and the Academy of Pharmaceutical Sciences at the Pharmaceutical Society of South Africa Conference, Sun City (with N Butler).
- 1997: *Issues in District Health Systems Management.* Valley Trust and the School of Public and Development Management, University of the Witwatersrand (part of a certificated course in Health Care Service Management, with J Smit, I Friedman).
- 1997: *District Health Systems and the Pharmacist: some Practicalities.* South African Pharmacy Student Federation Conference, Durban (with J Smit, F Suleman, A Suleman)
- 1997: *District Health Systems Implementation: the Issues.* Valley Trust and Department of Health Region F, KwaZulu-Natal Provincial Administration (with J Smit).
- 1995: *Rational drug use for primary care nurses.* Department of Community Nursing, Technikon Natal (with J Smit, ML McFadyen).

COURSES/ WORKSHOPS ATTENDED

- 2019: *Good Clinical Practice.* CITI Collaborative Institutional Training Initiative online course
- 2016: *Good Clinical Practice.* CITI Collaborative Institutional Training Initiative online course
- 2013: *Good Clinical Practice.* CITI Collaborative Institutional Training Initiative online course
- 2012: *Human Participants Protection Education for Research Teams.* National Cancer Institute online course.
- 2009: *Good Clinical Practice.* CITI Collaborative Institutional Training Initiative online course.
- 2008: *Human Participants Protection Education for Research Teams.* National Cancer Institute online course.
- 2006: *Good Clinical Practice and Source Documentation.* CAPRISA.
- 2005: *Information, pharmacovigilance and patient safety – approaches to data collection, analysis, dissemination and use.* International Pharmaceutical Federation and the Uppsala Monitoring Centre, Cairo, Egypt.
- 2004: *Good Clinical Practice.* PPD.
- 2003: *Evidence, money and drug selection: a short course in pharmacoconomics.* World Health Organization, Universities of Newcastle (Australia), Birmingham (UK) and Chulalongkorn (Thailand), Bangkok, Thailand.
- 2002: *Facilitator training for Curriculum 2001.* University of Natal.
- 1997: *Second African Course in Problem-based Pharmacotherapy Teaching.* University of Cape Town and World Health Organization.
- 1995: *Methods of Quality Assessment:* Network of Community -Oriented Educational Institutions for Health Sciences/ WHO, presented by Dr M Seefeldt, University of Illinois, at Manila Conference

- 1995: *Co-ordinators of Continuing Education Workshop*. Pharmaceutical Society of South Africa,, presented by Dr D Fielding, University of British Columbia, at Bloemfontein Conference
- 1993: *Computer Course (WordPerfect, Quattro-Pro)*. University of Durban-Westville.
- 1992: *Therapeutic Drug Monitoring Workshop*. Drug Studies Unit/Dept of Pharmacology, University of Durban-Westville.
- 1991: *Junior Management Certificate*. Commission for Administration Institute for Training.

REGISTRATION/ PROFESSIONAL and OTHER MEMBERSHIPS

South African Pharmacy Council (registered pharmacist P04619)

Pharmaceutical Society of South Africa (PSSA)

South African Association of Hospital and Institutional Pharmacists (SAAHIP)

South African Society for Basic and Clinical Pharmacology (SASBCP)

International Pharmaceutical Federation (FIP)

International Society for Pharmacoepidemiology (ISPE)

American Society of Health-system Pharmacists (ASHP)

Rotary International (Rotary Club of Westville)

RELEVANT EXPERIENCE

Clinical

- Provision of ward-based pharmacy services - expanded ward service to all hospital departments at King Edward Hospital over a 4-year period; daily participation in Intensive Care Rounds and Infectious Disease Round; provision of Parenteral Nutrition and drug information service
- Therapeutic Drug Monitoring service to Paediatric Epilepsy Clinic, Anticoagulant Clinic and to in-patients
- Service on Hospital Therapeutics Committee, Infection Control Committee and Antibiotic Sub-Committee
- Appointed to Expert Panel (Scheduling and Naming Committee) of the Medicines Control Council (2000 to date), Clinical Trials Committee (2015 to date)
- Chairman, KwaZulu-Natal Provincial Pharmacy and Therapeutics Committee (2003-2004); member (2002 to date)
- Member of the National Essential Medicines List Committee (2013 to date); co-chairperson of the Paediatric Expert Review Committee (2015 to date)
- Member of the WHO Expert Panel on Drug Policies and Management (2007 to date)

Teaching

- Guest lecturer for College of Nursing (King Edward) Post-basic courses in Theatre Science, Paediatrics, Orthopaedics, Advanced Midwifery (1988-1993)
- Honorary lecturer and External Examiner for Dept of Experimental and Clinical Pharmacology, University of Natal Medical School (BSc(Pharm), MMed(Clin Pharmacol), MBChB degrees) (1988-2001)
- Guest lecturer in Pharmacy Practice, University of Natal (1988-1993)
- In-service training of pharmacists and pharmacist's assistant trainees (1988-1993)
- Guest lecturer for Dept of Nursing, University of Natal (MSocSci degree), and Department of Community Nursing, Technikon Natal (Pharmacology for Primary Care Nurses)
- Lecturer for Dept of Pharmacology, University of Durban-Westville (BPharm, BPhysio, BMedSci, MMed. Sci(Pharmacol) degrees)
- Lecturer in Pharmacy Practice, University of Durban-Westville (BPharm and MPharm degrees) - course co-ordinator/Discipline Chair, Pharmacy Practice (1996, 1997, 2000-2001)
- Senior lecturer in Pharmacology/Therapeutics and Medicines Management, University of KwaZulu-Natal (BCur, BPharm, BOptom, MBChB, MClinPharm, MFamMed, MPH, MPharm, PG Dip HIV/AIDS Clin Mgt, Dip Occupational Health, PG Dip Public Health) – course co-ordinator for the MClinPharm programme (2002 to 2005), developer of the specialist track in Medicines Management, MPH programme (offered from 2005-2012), module co-ordinator of the Health Systems and Policy module, MPH programme (offered since 2014); module co-ordinator for the Rational Drug Use and Clinical Service Development and Evaluation modules, Pharm programme (since 2013)

Management

- Consultancy/facilitation services for district drug management developments in a series of urban and rural settings (Initiative for Sub-District Support and various consultancies with Management Sciences for Health, Health Research for Action)
- Formal training in Management with the Commission for Administration, and practice as Senior Pharmacist at King Edward VIII Hospital and as Discipline Chair, Pharmacy Practice at the University of Durban-Westville

- Involvement with policy issues at national, provincial, hospital and university level.

University

- Service on various bodies at the University of Durban-Westville: Faculty of Health Sciences Reconstruction and Development Task Force (1994); Faculty Research Committee (Secretary) (1995); Executive Committee of the Board of Faculty (1995, 1996); Ad-hoc Faculty Funding Committee (1995); Ad-hoc Faculty Constitution Committee(1995); Interdisciplinary Health Group (IDHIG) Management Committee (1996); Natal Institute for Community Health Education (NICHE) Policy Council (1996); Pharmacy Dept co-ordinator for the Research And Policy Studies Project (1995); Pharmacy Dept Management Committee (1996, 1997, 2000); Faculty representative on the University Ethics Committee (1997, 1998); University development work: closely involved in raising research and development funding (Health Systems Development Project (IDHIG), funded by the Health Systems Trust (1995); Research Capacity Development Project (Faculty of Health Sciences), supported by the Medical Research Council (1996); Research Capacity Development Project (Faculty of Health Sciences), supported by the Human Sciences Research Council (1996); Faculty Transformation Project (Faculty of Health Sciences), supported by the Tertiary Education Linkages Program of USAID (1997)
- Member, Faculty Board, Nelson R Mandela School of Medicine (2002-2011)
- Member, Senate of the University of KwaZulu-Natal (2015-2017)
- Senate Representative on the University Honorary Degrees Committee (2015-2017)

Professional leadership

- Service on various structures of the International Pharmaceutical Federation (FIP):
 Vice-President (Africa), Hospital Pharmacy Section (2001-2006)
 President, Hospital Pharmacy Section and member of Council (2007-2010)
 Member, Executive Committee of the Board of Pharmaceutical Practice (2009-2010)
 Chairman, Board of Pharmaceutical Practice and member of the Bureau and Council (2011-2014)
 Vice-President and member of the Bureau and Council (2015-2018)
- Service on various structures of the South African Association of Hospital and Institutional Pharmacists (SAAHIP):
 Executive Committee of the Natal Coastal Branch (1993, 1994; 2008; 2011-2020)
 Chairperson Natal Coastal Branch (1995-1996, 2005-2007)
 National Executive Committee (1995-2000, 2005-2007)
 Academic Convenor of 9th SAAHIP Conference 1995; 21st SAAHIP Conference 2007; 22nd SAAHIP Conference 2008; 28th SAAHIP Conference 2014; 29th SAAHIP Conference 2015
 Vice-President (1996, 1997)
 President (1998, 1999)
- Service on various structures of the Pharmaceutical Society of South Africa (PSSA)
 Member, national Constitutional Task Group (2000 - date)
 Member, Executive Committee, KwaZulu-Natal Coastal branch (2003-2007)
 Academic Convenor of the joint PSSA/Commonwealth Pharmacist's Association Conference (2011)
 Chairman, Fellows Committee (2020-2022)
- Member, Council of the National Asthma Education Programme (2005-2009)
- Co-convenor of the launch of the KwaZulu-Natal Pharmacy Forum (1995)
- Member, National Consultative Health Forum (1996-1999)
- Member, International Steering Group, Health Action International (HAI) (2001-2004)

RESEARCH INTERESTS

1. Policy analysis (particularly the processes of development and implementation of Medicines Policies)
2. Rational medicines use (particularly in the elderly and in relation to antimicrobial use).
3. The application of combination antiretroviral therapy (cART) in resource-constrained settings.